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1.1 NOVEL DRUG DELIVERY SYSTEM 
Novel drug delivery research aims to conveniently administer complex drugs 
to the target tissue in the biological system in a more stable and reproducible 
controlled way so that it would achieve higher activity at a minimal dose for 
prolonged period at the site devoid of side effects. Entrapment of a drug into a 
polymeric system may protect the drug from inactivation and help to retain its activity 
for prolonged durations, decrease its toxicity, dosing frequency and offers flexibility 
in administration. A number of novel drug delivery systems have emerged 
encompassing various routes of administration, to achieve controlled and targeted 
drug delivery.
 1
 
The method by which a drug is delivered can have a significant effect on its 
efficacy. Some drugs have an optimum concentration range within which maximum 
benefit is derived, and concentrations above or below this range can be toxic or 
produce no therapeutic benefit at all. On the other hand, the very slow progress in the 
efficacy of the treatment of severe diseases, has suggested a growing need for a 
multidisciplinary approach to the delivery of therapeutics to targets in tissues. From 
this new ideas on controlling the pharmacokinetics, pharmacodynamics, non-specific 
toxicity, immunogenicity, biorecognition, and efficacy of drugs were generated. These 
new strategies, often called drug delivery systems, are based on interdisciplinary 
approaches that combine polymer science, pharmaceutics, bioconjugate chemistry, 
and molecular biology.  
To minimize drug degradation and loss, to prevent harmful side-effects and to 
increase drug bioavailability and the fraction of the drug accumulated in the required 
zone, various drug delivery and drug targeting systems are currently under 
development. Among drug carriers one can name soluble polymers, microparticles 
made of insoluble or biodegradable natural and synthetic polymers, microcapsules, 
cells, cell ghosts, lipoproteins, liposomes and micelles. The carriers can be made 
slowly degradable, stimuli-reactive (e.g., pH- or temperature-sensitive), and even 
targeted (e.g., by conjugating them with specific antibodies against certain 
characteristic components of the area of interest).
2
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1.2 TARGETED DRUG DELIVERY SYSTEM (TDDS) 
Targeted drug delivery is defined as a method of delivering medication to a 
patient in a manner that increases the concentration of the medication in certain parts 
of the body relative to others. In traditional drug delivery systems like oral ingestion 
and IV injection, the medication is distributed throughout the body through the 
systemic blood circulation. For most drugs, only a small portion of the medication 
reaches the affected organ. Targeted drug delivery system aims at concentrating the 
medication in the tissues of interest and hence reducing the relative concentration of 
the medication in the remaining tissues. This helps in reducing the side effects and 
improving the efficacy.
3
 
1.2.1 CHARACTERISTICS OF AN IDEAL TDDS 
 Non-toxic, non-immunogenic, physically and chemically stable in-vivo and  
in-vitro.  
 Should restrict drug distribution to target cells or tissues or organs.  
 Should have uniform capillary distribution. 
 Controllable rate and therapeutic amount of drug release. 
 Drug release should not affect the drug action. 
 Drug leakage during transit must be minimal 
 Carriers used should be bio-degradable or readily eliminated from the body. 
 The preparation should be easy or reasonably simple and cost effective. 
Targeted Drug Delivery Systems have been classified as follows:
4
  
Classification I
 
1. Site-directed targeting 
2. Site-avoidance targeting 
Classification II  
Site-directed targeting can further be classified as 
1. Passive targeting: refers to natural or passive disposition of a drug-carrier 
based on the physiochemical characteristics of the system in relation to the 
body. 
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2. Active targeting: refers to alteration of the natural disposition of the drug 
carrier, directing it to specific cells, tissues or organs. For e.g. use of ligands  
or monoclonal antibodies which can target specific sites. 
3. Inverse targeting 
4. Dual targeting 
5. Double targeting 
6. Combination targeting  
Classification III 
Active targeting can be further classified into three broad categories- 
1. First order targeting: refers to DDS that delivers the drugs to the capillary 
bed or to the active site. 
2. Second- order targeting: refers to DDS that delivers the drug to a specific 
cell type such as the tumour cells and not to the normal cells. 
3. Third- order targeting: refers to DDS that delivers the drug to the 
intracellular site of the target cells. 
Classification IV
 
Active targeting can also be categorised as  
 
1. Organ targeting 
2. Cellular targeting  
3.  Sub-cellular targeting 
Classification V
 
1. Biochemical targeting 
2. Biomechanical targeting 
3. Biophysical targeting 
4. Bioadhesive targeting 
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Classification VI
 
1. Carrier dependent targeting 
2. Carrier independent targeting 
Drug targeting requires carriers for selective delivery which can: 
 Protect the drug from degradation after administration 
 Improve transport or delivery of drug to cells 
 Decrease clearance of drug 
 Combination of the above 
 
1.2.2 CARRIERS FOR DRUG TARGETING 
 
1. Carriers covalently bonded to drug: where the drug release is required 
for pharmacological activity. 
 
2. Carriers not covalently bonded to drug: where simple uncoating of the 
drug is required for pharmacological activity. Eg. Liposomes.  
The various carriers used for drug targeting are- 
 Microspheres 
 Nanoparticles 
 Polymeric carriers  
 Albumin  
 Lipoprotein  
 Liposomes 
 Niosomes 
 Antibodies 
 Cellular carriers and  
 Macromolecules.  
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1.3 COLON TARGETED DRUG DELIVERY SYSTEM (CTDDS) 
CTDDS means targeted delivery of drugs into the lower GIT, which occurs 
primarily in the large intestine (i.e. colon). In the past two decades, the pharmaceutical 
scientists have extensively investigated in the area of colonic region for targeted drug 
delivery.
5
 Colon targeting depends on exploiting a unique feature of specific site and 
protecting the drug until it reaches to the site. 
Targeted drug delivery to the colon is highly desirable for local treatment of a 
variety of bowel diseases such as inflammatory bowel disease, amebiosis, colonic 
cancer and for local treatment of local colonic pathologies, and the systemic delivery 
of protein and peptide drugs.
6
 The advent of slow release technologies increases the 
chances for a drug to be released in the colon and thus this organ has an important role 
to play in drug absorption from oral sustained release formulations.
7 
 
Figure 1: Human Digestive System 
1.3.1 Advantages of CTDDS:  
 Reducing the side effects that occur because of release of drugs in the upper 
GIT or  unnecessary systemic absorption 
 The colon is attracting interest as a site where poorly absorbed drug molecule 
may have an improved bioavailability.
5
 
 By producing the friendlier environment for peptides and proteins when 
compared to upper GIT. 
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 Preventing the gastric irritation produced by oral administration of NSAIDS. 
 Delayed release of drugs to treat angina, asthma and rheumatoid arthritis. 
1.3.2 Limitations of CTDDS:  
 Colon is difficult to access due to its location at the distal portion of the GIT. 
 Successful delivery requires the drug to be in solution before it arrives in the 
colon, but the fluid content in the colon is lower and more viscous than in 
upper GIT, which is the limiting factor for poorly soluble drugs. 
 Lower surface area and relative tightness of the tight junctions in the colon can 
restrict drug transport across the mucosa into the systemic circulation. 
1.3.3 Drugs suitable for CTDDS
8
  
The different categories of drugs suitable for colon drug delivery are shown in table 1. 
  Table 1: Colon targeting Diseases, Drugs and Sites 
S.No. Target sites Disease conditions Drug and active agents 
1. Topical action 
Inflammatory Bowel Disease, 
Irritable Bowel Disease 
Hydrocortisone, 
Budesonide, 
Prednisolone, 
Sulfasalazine, 
Olsalazine, Mesalazine, 
Balsalazide 
2. Local action 
Chronic Pancreatitis, Fibrosis, 
colorectal cancer 
Digestive enzyme 
supplements 
5-Flourouracil 
3. Systemic action 
To prevent gastric irritation NSAIDS 
To prevent first pass 
metabolism of orally ingested 
drugs 
Steroids 
Oral delivery of peptides Insulin 
Oral delivery of vaccines Typhoid 
Drugs poorly absorbed from 
GIT 
Ibuprofen, Isosorbides 
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1.3.4 Factors to be considered in the design of colon targeted drug 
delivery system 
Colon act as Black-box of the body and site specificity is difficult task. 
Various factors are to be considered for designing colon targeted drug delivery. 
1.3.4.1 Anatomy and Physiology of colon
8
: 
      The GIT consists of parts from mouth to anus. It mainly consists of stomach, 
small intestine and large intestine.  
       The large intestine extends from the distal end of the ileum (ileocecal junction) 
to the anus measuring about 1.5meters in length and is divided into three parts- colon, 
rectum and anal canal. The colon is the upper five feet of the large intestine and 
mainly situated in the abdomen. It is a cylindrical tube that is lined by mucosa. It 
includes caecum, colon and rectum. Caecum forms the first part of the colon and leads 
to the right colon or the ascending colon followed by the transverse colon, the 
descending colon, sigmoid colon, rectum and the anal canal. The major function of the 
colon is to create a suitable environment for the growth of colonic microorganisms, 
absorption of potassium and water from lumen, storage reservoir of faecal contents 
and expulsion of the contents of the colon at an appropriate time. The retention time of 
large intestine is 3-10hr.  
 
Figure 2: Anatomy of Colon 
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1.3.4.2 pH of Colon:
8 
 The pH of GIT is subject to both inter and intra subject variations due to diet, 
diseased state, etc.  This change in the pH in different parts of GIT is the basis for the 
development of colon targeted drug delivery systems. Coating with different polymers 
is done to target the drug to the site.  
Table 2: pH in different parts of Colon  
 
  
 
 
 
 
1.3.4.3 Colonic micro flora & their enzymes: 
 Drug release in various parts of GIT depends upon the presence of intestinal 
enzymes. Gut juices and gut microflora. The enzymes are used to degrade 
coatings/matrices as well as to break bonds between an inert carrier and an active 
agent (i.e., release of a drug from a prodrug) resulting in the drug release from the 
formulation. Almost 400 distinct bacterial species have been found, out of which 20% 
to 30% are of the genus Bactericides. The upper region of GIT consists of very small 
number of bacteria and predominantly gram-positive facultative bacteria. The 
concentration of bacteria in the human colon is around 1000 CFU/ml. The most 
important anaerobic bacteria’s are Bactericides. Bifidobacterium, Eubacterium, 
Peptococcus, Peptostreptococcus, Ruminococcus, Propionibacterium and clostridium.  
 
 
 
Part of GIT pH 
Stomach 
Fasted state - 1.5 to 2 
Fed state 2 to 6 
Small intestine 6.6 to 7.5 
Colon 
Ascending colon 
Transverse colon 
Descending colon 
 
6.4 
6.6 
7 
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1.3.5 COLONIC ABSORPTION OF DRUGS
7
  
 The surface area of the colon is much less compared to small intestine and is 
compensated by absence of endogenous digestive enzymes and long residence time of 
colon (10-24 hours). Routes for colonic absorption are:  
 Passes through colonocytes (Trans cellular transport- most lipophilic 
drugs). 
 Passes between adjacent colonocytes (Para cellular transport- most 
hydrophilic drugs). 
Drugs shown to be well absorbed includes Glibenclamide, Diclofenac. 
Theophylline, Ibuprofen, Metoprolol and Oxyprenolol. Drugs shown to be less 
absorbed includes Furosemide, pyretanide, Buflomedil, Atenolol, Cimetidine, 
Hydroclorthiazide, Lithium and Ciprofloxacin.  
1.3.6 APPROACHES FOR SITE SPECIFIC DRUG DELIVERY TO COLON
8
 
Approaches used for site-specific drug delivery are: 
 Primary approaches for CTDDS  
 pH sensitive polymer coated delivery to colon 
 delayed (time controlled release system) release drug delivery to colon. 
 Microbially triggered drug delivery to colon 
 Prodrug approach for drug delivery to colon 
 Azo-polymeric approach for drug delivery to colon 
 Polysaccharide based approach drug delivery to colon 
 Newly developed approaches for CTDDS   
 Pressure controlled drug delivery system 
 CODES 
 Osmotic controlled drug delivery to colon (OROS-CT) 
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1.3.6.1 pH-based systems 
 Enteric polymers are insoluble in stomach contents and they prevent drug 
dissolution until the formulation passes into the small intestine. But, they may start to 
dissolve in the lower small intestine, and hence the site-specificity of formulations 
becomes poor. The decline in pH from the end of small intestine to the colon can also 
result in some problems. Lengthy lag times in the ileocecal junction or rapid transit 
through the ascending colon results in poor site-specificity of enteric-coated single-
unit formulations.
8
 Asacol
®, 
Claversal
®
, Mesazal
®
, Calitoflak
®
, Entocort
®
 etc. are 
examples of pH based systems. 
 
1.3.6.2 Delayed (time controlled release system) release drug delivery to colon. 
 In this approach, the basic principle is the release of the drug after a 
predetermine lag time from dosage form at the site of action at right time and in right 
amount.  
 
Figure 3: Time controlled and time dependent system 
 
Disadvantages of this system are 
(i) Gastric emptying time varies markedly between subjects or in a manner 
dependent on type and amount of food intake.  
Gastrointestinal movement, would result in the change in gastrointestinal   
transit of the drug. 
(ii) Accelerated transit through different regions of the colon has been observed in   
patients with the IBD, diarrhoea and ulcerative colitis.  
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1.3.6.3 Microbially triggered drug delivery to colon:  
 The basic principle involved in this method is degradation of polymers present 
in the drug delivery systems by microflora present in the colon, thereby release of 
drug load into colonic region. The colonic bacteria are predominately anaerobic in 
nature and secrete enzymes that are capable of metabolizing substrates such as 
carbohydrates and proteins that escape the digestion in the upper GI tract.  
The enzymes present in the colon are  
1. Reducing enzymes:  
 Nitroreductases 
  Azoreductases 
 N-oxide reductases  
 Sulfoxide reductases 
  Hydrogenases  
2. Hydrolytic enzymes:  
 Esterases  
 Amidases 
  Glycosidases 
  Glucuronidases. 
 
Because of the presence of the biodegradable enzymes only in the colon, the 
use of biodegradable polymers for colon specific drug delivery seems to be a more 
site-specific approach as compared to other approaches. These polymers shield the 
drug from the environments of stomach and small intestine and are able to deliver the 
drug to the colon. On reaching the colon, they undergo assimilation by micro-
organism or degradation by enzyme or break down of the polymer back bone leading 
to a subsequent reduction in their molecular weight and thereby loss of mechanical 
strength. They are then unable to hold the drug entity any longer. 
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Pro drug approach  
Pro drug is pharmacologically inactive derivative of a parent drug molecule 
that requires spontaneous or enzymatic transformation in-vivo to release the active 
drug. For colonic delivery the pro drug are designed to undergo minimal absorption 
and hydrolysis in the tracts of upper GIT and undergo enzymatic hydrolysis in the 
colon, there by releasing the active drug moiety from the drug carrier. It is not very 
versatile approach as its formulation depends upon the functional group available on 
the drug moiety for chemical linkage.  
Azo-polymeric prodrugs:   
 Newer approaches are aimed at use of polymers as drug carriers for drug 
delivery to the colon. Both synthetic as well as naturally occurring polymers are used 
for this purpose. Sub synthetic polymers have been used to form polymeric pro drug 
with azo linkage between the polymer and drug moiety. These have been found to be 
similarly susceptible to cleavage by the azoreductase in the large bowel.  
Polysaccharide based delivery systems: 
 Naturally occurring polysaccharides are found in abundance, widely available, 
are inexpensive and are available in a variety of structures with varied properties. 
They can be easily modified chemically and biochemically and are high stable, safe, 
nontoxic, hydrophilic and gel forming and biodegradable. These include naturally 
occurring polysaccharides obtained from plants, animals (chitosan, chondroitin), algae 
(alginates) and microbials (dextran). They are broken down by the colonic microflora 
to simple saccharides. So these fall into the category of “generally regarded as safe” 
 
1.3.6.4   NEWLY DEVELOPED APPROACHES FOR CTDDS 
(i) Pressure-controlled drug-delivery systems (PCDCs) 
 (ii) Novel colon targeted delivery system (CODES
TM
)   
  (iii) Osmotic controlled drug delivery (OROS-CT) 
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Table 3: Marketed Colon- Targeting Dosage Forms 
S. 
No. 
Drug 
Trade 
name 
Formulation 
Presenta
tion 
Dose 
1. Mesalamine Asacol
® 
Eudragit-S coated 
tablets 
(dissolves at pH 7) 
400 mg 
tablets 
0.8- 2.4 g/d 
2. Mesalamine 
Claversal
®
 
 
Mesazal
®
 
 
Calitoflak
®
 
Eudragit-L coated 
tablets 
(dissolves at pH 6) 
Tablets 1.0 – 2.0g/d 
3. Mesalamine Salofac
®
 
Eudragit-L coated 
tablets 
(dissolves at pH 6) 
400 mg 
tablets 
1.0 – 4.0g/d 
4. Sulfasalzine Azulfidine 
Cellulose acetate 
phthalate coated 
tablets 
500 mg 
tablets 
2.0 g/d 
5. Sulfasalazine 
Colo- 
Pleon
®
 
Enteric coated 
tablets 
500 mg 
tablets 
2.0g/d 
6. Budesonide Entocort
®
 
Eudragit-L coated 
beads (dissolves at 
pH6) 
3 mg 
capsules 
9 mg/d 
7. Budesonide 
Budenofalk
®
 
Eudragit-S coated 
tablets (dissolves 
at pH7) 
3 mg 
capsules 
9 mg/d 
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1.4 MICROSPHERES
 
Microspheres are characteristically free flowing powders consisting of proteins 
or synthetic polymers having a particle size ranging from 1-1000µm.  
Microspheres are defined as “monolithic spheres or therapeutic agent 
distributed throughout the matrix either as a molecular dispersion of particles” or can 
be defined as structure made up of one or more miscible polymers in which drug 
particles are dispersed at the molecular or macroscopic level.  
There are two types of microspheres: 
 Microcapsules 
 Micro matrices  
Microcapsules are those in which entrapped substance is distinctly surrounded 
by distinct capsule wall and micro matrices in which entrapped substance is dispersing 
throughout the microspheres matrix. They are made up of polymeric, waxy, or other 
protective materials, that is biodegradable synthetic polymers and modified natural 
products. 
1.4.1 TYPES OF MICROSPHERES 
14,28
  
1. Bioadhesive microspheres 
2. Floating microspheres  
3. Radioactive microspheres  
4.  Magnetic microspheres14  
 This kind of delivery system is very much important which localizes the drug 
to the disease site. In this larger amount of freely circulating drug can be replaced by 
smaller amount of magnetically targeted drug. Magnetic carriers receive magnetic 
responses to a magnetic field from incorporated materials that are used for magnetic 
microspheres like chitosan, dextran etc. The different types are therapeutic magnetic 
microspheres and diagnostic microspheres. 
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5. Polymeric microspheres 
5 (a) Biodegradable polymeric microspheres  
 Natural polymers such as starch are used with the concept that they are 
biodegradable, biocompatible, and also bioadhesive nature. These polymers prolongs 
the residence time when contact with mucous membrane due to it’s high degree of 
swelling property with aqueous medium, results gel formation. The rate and extent of 
drug release is controlled by concentration of polymer and the release pattern in a 
sustained manner. The main drawback is in clinical use drug loading efficiency of 
biodegradable microspheres is complex is difficult to control the drug release. 
5 (b) Synthetic polymeric microspheres  
 The interest of synthetic polymeric microspheres are widely used in clinical 
application, moreover that also used as bulking agent, fillers, embolic particles, drug 
delivery vehicles etc and proved to be safe and biocompatible. The limitation is that 
these microspheres tend to migrate away from injection site and lead to potential risk, 
embolism and further organ damage. 
 
1.4.2. METHODS OF PREPARATION28  
1. Emulsion solvent evaporation technique 
2. Emulsion-solvent diffusion technique 
3. Emulsion cross linking method 
4. Phase separation/ Coacervation 
5. Spray drying and spray congealing technique 
6. Multiple emulsion method 
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1.4.3 DRUG RELEASE MECHANISM FROM MICROSPHERES
28 
Drug release from the microsphere occurs by general mechanism including 
diffusion, polymer degradation, and hydrolysis/erosion.  
 
Figure 4: Release mechanism of Microspheres 
Diffusion 
On contact with aqueous fluids in the gastrointestinal tract (GIT), water 
diffuses into the interior of the particle. Drug dissolution occurs and the drug solutions 
diffuse across the release coat to the exterior. 
 
Figure 5: Drug Release from Diffusion 
Erosion 
Some coatings can be designed to erode gradually with time, thereby releasing 
the drug contained within the particle. The polymer erosion, i.e. loss of polymer is 
accompanied by accumulation of the monomer in the release medium. The erosion of 
the polymer begins with the changes in the microstructure of the carrier as the water 
penetrates within it leading to the plasticization of the matrix. 
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1.5 MAGNETIC MICROSPHERES
9 
Drug delivery systems based on microparticles sensitive to a remotely applied 
magnetic field appear on the top of the (bio) technological innovations, because the 
magnetic field, if used in a therapeutic level, does not affect biological tissues.
10 
Magnetic drug targeting is a pioneering concept proposed by Freeman et al. in 
1960 in which fine iron particle could be transported through the vascular system and 
concentrated at a particular point in the body with the aid of magnetic fields to achieve 
prolonged release with high, localized concentrations of drug by retention of the 
carriers in the region of interest.
32 
Magnetically targeted drug delivery system (MT-DDS) involves binding a 
drug to a small biocompatible magnetically active component, entrapped in the 
biodegradable polymer matrix and formulating it into a pharmacologically active 
stable formulation, which is injected into the blood stream and using a high-gradient 
magnetic field to pull them out of suspension in the target region.
9
  
According to FDA, Magnetic Microspheres are supramolecular particles that 
are small enough to circulate through capillaries without producing embolic occlusion 
but are sufficiently susceptible (ferromagnetic) to be captured in micro vessels and 
dragged into the adjacent tissues by magnetic fields of 0.5-0.8 T. Magnetic 
microspheres (MM) vary widely in quality, sphericity, uniformity, particle size and 
particle size distribution. The appropriate microspheres need to be chosen for each 
unique application.
9
  
Magnetic microspheres are often formulated with an intention to produce a 
depot near the target organ, by placing a suitable magnet near it. From the depot, the 
drug will be released slowly and carried to the target organ through blood. By 
localizing the drug carrier near the target organ, unwanted distribution of drug to non 
target organ can be avoided. This approach will localize the drug only at target site 
and minimize the drug-induced toxicity. The amount and rate of drug delivery via 
magnetically responsive microspheres can be regulated by varying (i) size of 
microspheres; (ii) drug content; (iii) magnetite content; (iv) hydration state; (v) drug 
release characteristic of carrier.
11
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1.5.1 MECHANISMWISE DIFFERENCE BETWEEN MAGNETIC AND   
NON-MAGNETIC MICROSPHERES
9,14
 
 
 
           Figure 6: Release mechanism of Microspheres 
 
Various nonmagnetic micro carriers (nanoparticles, microspheres and micro 
particles etc.) are successfully utilized for drug targeting but they show poor site 
specificity and are rapidly cleared off by RES (reticuloendothelial system) under 
normal circumstances. Magnetism plays a vital role in these cases, magnetic carriers 
such as magnetite, iron, nickel, cobalt, neodymium-iron-boron or samarium-cobalt are 
used; out of which magnetite being the most common one. It offers the various 
advantages like (i) Magnetite is well tolerated by the body,(ii) magnetic field is 
harmless to the body when compared to the traditional radiation methods; (iii) 
adaptable to any part of the body and, (iv) upto 60% of injected dose can be deposited 
and released in a controlled manner in selected non-reticuloendothelial organs due to 
its ability to minimize RES clearance.
11 
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1.5.2 CONCEPT AND PRINCIPLE BEHIND MAGNETIC TARGETING 
13,14 
 
Figure 7:  Magnetic Targeting 
 
Figure 8: Principle of Magnetic Drug Targeting 
Magnetic drug transport is based on the fact that the drug can be either 
encapsulated into a magnetic microsphere or conjugated on the surface of the 
microsphere. When loaded MM is introduced into a blood vessel (such as artery) 
supplying an in-vivo target site, accumulation takesplace in the target site to which 
magnetic field is applied which allows them to deliver the drug locally. Efficiency of 
accumulation of magnetic carrier on physiological carrier depends on physiological 
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parameters e.g. particle size, surface characteristics, field strength and blood flow rate 
etc. Restriction of the microspheres only in the microvasculature can be achieved by 
taking advantages of the physiological difference in the linear flow velocity of blood 
in large artery (15-20 cm/sec) versus that in capillaries (0.05cm/sec). The magnetic 
field helps to extravagate the magnetic microsphere into the target area. Very high 
concentrations of potent drugs can be achieved near the target site without any toxic 
effects to normal surrounding tissue or to whole body.
12 
1.5.3  MAGNETIC PROPERTIES 11, 12
 
Magnetic particles for bio-seperation consists of one or more magnetic cores 
with a coating matrix of polymers, silica or hydroxyl apatite with terminal 
functionalized groups, the magnetic core consists of either magnetite (Fe3O4) or 
magnetite (gamma Fe3O4 ) with superparamagnetic or ferromagnetic properties.  
Superparamagnetism is when the dipole moment of a single-domain particle 
fluctuates rapidly in the core due to the thermal excitation so that there is no magnetic 
moment for macroscopic time scales. Thus, these particles are non-magnetic in the 
absence of external magnetic field but do develop a mean magnetic moment in an 
external magnetic field. Advantages of superparamagnetic particles are easy re 
suspension, large surface area, slow sedimentation and uniform distribution of the 
particles in the suspension media. Once magnetized, the particles behave like small 
permanent magnets, so that they form aggregates or lattice due to magnetic 
interaction.
11 
 
Figure 9: Superparamagnetic  particles and  Ferromagnetic particles                   
(a) under the influence of external magnetic field;   
                     (b) in the absence of an external magnetic field 
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Ferromagnetism means that the particles have a permanent mean magnetic 
moment. Here, the larger effective magnetic anisotropy suppresses the thermally 
activated motion of the core moments. Advantages of ferromagnetic particles are very 
strong magnetic properties and therefore the fast separation with an external magnetic 
field even in viscous media.
11 
                
Figure 10: Alignment in Superparamagnetic particles and  Ferromagnetic particles    
(a) under the influence of external magnetic field;                                                 
(b) in the absence of an external magnetic field 
 
1.5.4 MAGNETITE12 
Also called as ferric ferrous oxide, ferrous ferrite, tri iron tetra oxide, and black 
iron oxide. Magnetic iron oxide chemical formula FeO .Fe2O3 having a molecular 
weight of 231.55 with a chemical composition of Fe = 72.36%, O = 27.64%. The 
ferromagnetic material when incorporated into microspheres makes them magnetically 
responsive, so that they can be concentrated to the desired site by applying some 
external magnetic field. 
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While employing magnetic particles in drug delivery, an ideal drug carrier should be: 
 Small enough to remain in circulation after injection. 
 Biocompatible i.e., non-toxic and non-immunogenic. 
 Able to cross the anatomic barriers. 
 Recognized only by the target cells. 
 Not releasing the drug before reaching the target. 
 
1.5.4 MAGNET DESIGN12 
Magnetic targeting results from the force exerted by a gradient magnetic field. 
The relationship of magnetic force to field gradient and magnetic moment of particles 
is expressed by the following equation: 
 
Magnetic force = Magnetic moment x Magnetic field gradient 
 
It is clear from the equation that increased magnetic moments offer forces 
sufficient for the extravascular migration at proportionately lower field gradients. The 
magnetic moments of the microspheres can be increased in following three ways: 
a) By magnetizing the sphere to saturation level prior to vascular targeting. 
b) By clustering magnetite at the centre of each sphere to produce larger 
macrodomains. 
c) By substituting one of the newer ferromagnetic materials that has higher 
susceptibility than magnetite.
12
 
In magnetic microspheres with high magnetic content, the external magnetic 
field strength required is less, but if high magnetic content is present, then the space 
available for drug is less and hence the magnitude of magnetic content and drug 
should be delicately balanced to have an efficient therapeutic system. Satisfactory 
targeting of microspheres (with 20% magnetite) could be achieved using magnets of 
0.55 to 0.80 T field straight. 0.01 T T/mm field gradient and 0.4 to 0.8 cm 
(diameter).
12    
 
INTRODUCTION 
 
Department of Pharmaceutics, Madras Medical College Page 24 
 
1.5.5 FACTORS AFFECTING  THE PROPERTIES OF MAGNETIC   
MICROSPHERES
9,13
  
 
1. Polymer selection  
Materials 
Used 
Types Examples 
Synthetic 
Polymers 
 Non-biodegradable 
polymers 
 
 Biodegradable polymers 
PMMA, Acrolein, 
Glycidyl methacrylate 
 
Epoxy polymers, 
lactides, glycolides and 
their co-polymers, 
polyanhydrides 
Natural 
polymers 
 Proteins 
 
 
 Carbohydrates 
 
 
 Chemically modified 
carbohydrates 
Albumin, Gelatin,  
Collagen 
 
Agarose, Chitosan, 
Carageenan, Starch 
 
Poly dextran, Poly 
starch 
 
  
   Table 4:  List of polymers used for the preparation of MM 
 
2. Choice of solvent 
  Should be able to dissolve the chosen polymer 
 Poorly soluble in continuous phase 
 High volatility and a low boiling point 
 Low toxicity 
 Alternative components ( dispersed phase) 
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3. Co-solvent: organic solvents miscible with water such as methanol and 
ethanol. 
4. Porosity generator: increases degradation rate of polymer and improves 
drug release rate. e.g. sephadex ( cross-linked dextran gel). 
 
5. Continuous phase:  
a) Surfactant : 
  Reduces surface tension of continuous phase. 
 Avoids coalescence and agglomeration of drops. 
 Stabilizes emulsion. 
 
Various types are 
Surfactant type Examples 
 
Non ionic 
partially hydrolysed 
PVA, methyl cellulose, 
Tween, Span 
Anionic sodium dodecyl sulphate, 
SLS 
Cationic tri methyl ammonium 
bromide 
 
Table 5:  List of surfactants used for the preparation of MM 
 
b) Alternative components: 
 Antifoaming agents 
 Anti-agglomerating agents. 
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1.5.7  PREPARATION OF MAGNETIC MICROSPHERES 
13
 
1.5.7.1  Selection of Drugs 
In the selection of a drug for the formulation of MM, following points are to be 
considered: 
 The drug is so dangerous or labile that we cannot allow it to circulate 
freely in the blood stream. 
 The agent is so expensive, that we cannot afford to waste 99.9% of it. 
 Requires a selective, regional effect to meet localized therapeutic 
objective. 
 Requires an alternative formulation essential to continue treatment in 
patients whose systemic therapy must be temporarily discontinued due 
to life threatening toxicity directed at selective organs. 
 Examples of drugs used: Adriamycin, Amphotericin B, Membrane 
active agents, Prostaglandins, Immuno suppressants etc. 
1.5.7.2 Methods of Preparation  
1. Phase Separation Emulsion Polymerization
9
 
Phase Separation method is specially designed for preparing the reservoir type of              
the system to encapsulate water soluble drugs. E.g., peptide, proteins. 
In matrix type device, the drug is soluble in the polymer phase.  Hence, certain   
preparations are of matrix type particularly, when the drug is hydrophobic in nature. 
E.g.,steroids. 
This process is based on the principle of decreasing the solubility of the polymer 
in the organic phase to affect the formation of polymer rich phase called the 
coacervates. In this method, the drug particles are dispersed in a solution of the 
polymer and addition of an incompatible polymer/ non-solvent/salt / change in pH to 
the system (magnetic fluid) which makes first polymer to phase separate and engulf 
the drug particles.  
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Figure 11: Coacervation process 
 
2. Continuous Solvent Evaporation11 
In this method the drug and polymer (carrier) are dissolved in appropriate 
volatile organic solvent and then magnetite is added to this solution along with stirring 
in order to form a homogeneous suspension. This suspension is added to an 
immiscible auxillary solution along with vigerous stirring. The volatile organic 
solvent is evaporated slowly at 22- 30
0
 C to form microspheres. Microspheres are then 
centrifuged and freeze dried and stored. 
       
Figure 12: Solvent evaporation technique                                                      
3. Ionic Gelation Method7 
Inotropic
 
gelation is based on the ability of polyelectrolytes to cross link in the 
presence of counter ions to form hydrogel beads also called as microspheres. 
Microspheres are spherical cross-linked hydrophilic polymeric entity capable of 
extensive gelation and swelling in simulated biological fluids and the release of drug 
through it controlled by polymer relaxation. The hydrogel beads are produced by 
dropping a drug loaded polymeric solution into the aqueous solution of polyvalent 
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cations. The cations diffuses into the drug loaded polymeric drops, forming a three 
dimensional lattice of ionically cross-linked moiety.  
 
4. Solvent Extraction Method7 
This method involves removal of organic phase by extraction of the organic 
solvent. Isopropanol can be used as water miscible organic solvent. By extraction with 
water, organic phase is removed. Hardening time of microspheres can be decreased by 
this method. 
 
5. Spray drying and spray congealing technique35 
 
Figure 13: Spray drying technique 
 
These methods are based on the drying of the mist of the polymer and drug in 
the air. Depending upon the removal of the solvent or cooling of the solution, the two 
processes are named spray drying and spray congealing respectively. The polymer is 
first dissolved in a suitable volatile organic solvent such as dichloromethane, acetone, 
etc. The drug in the solid form is then dispersed in the polymer solution under high 
speed homogenization. This dispersion is then atomized in a stream of hot air. The 
atomization leads to the formation of the small droplets or the fine mist from which 
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the solvent evaporates instantaneously leading the formation of the microspheres in a 
size range 1-100 μm. Microparticles are separated from the hot air by means of the 
cyclone separator while the traces of solvent are removed by vacuum drying. One of 
the major advantages of the process is  
1. Feasibility of operation under aseptic conditions.  
2. The spray drying process is used to encapsulate various penicillins. 
Thiamine mononitrate14 and sulpha ethylthiadizole15 are encapsulated in 
a mixture of mono- and diglycerides of stearic acid and palmitic acid using 
spray congealing. 
3.  Very rapid solvent evaporation, however leads to the formation of porous 
microparticles.  
 
6   Multiple emulsion method
11
 
Multiple emulsion method involves formation of (o/w) primary emulsion (non 
aqueous drug solution) and then addition of primary emulsion to external oily phase to 
form o/w/o emulsion followed by either addition of cross linking agent 
(glutaraldehyde) and evaporation of organic solvent. Multiple emulsion method of 
preparation is ideal for incorporating poorly aqueous soluble drug, thus enhancing its 
bioavailability.  
7 Emulsion cross linking method
17
 
In this method drug was dissolved in aqueous gelatin solution which was 
previously heated for 1hr at 40°C. The solution was added drop wise to liquid paraffin 
while stirring the mixture at 1500 rpm for 10min at 35°C, results in W/O emulsion 
then further stirring is done for 10min at 15°C. Thus the produced microspheres were 
washed respectively three times with acetone and isopropyl alcohol which then air 
dried and dispersed in 5ml of aqueous glutaraldehyde saturated toluene solution at 
room temperature for 3hrs for cross linking and then was treated with 100ml of 10mm 
glycerine solution containing 0.1% w/v of tween 80 at 37°C for 10min to block 
unreacted glutaraldehyde.  
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1.5.8 PHYSICOCHEMICAL CHARACTERIZATION AND EVALUATION   
METHODS 
5,9
 
1. Particle size and shape: Laser microscopy, Scanning electron microscopy 
2. Electron spectroscopy for chemical analysis: Determines surface chemistry 
3. Attenuated total reflectance Fourier Transform-Infrared Spectroscopy: 
Determines degradation of polymeric matrix 
4. Capture efficiency: % Entrapment : UV spectroscopy 
5. Thermal analysis: Differential Scanning Calorimetry (DSC) 
6. Swelling index: Characterization of microspheres is performed with swelling 
index technique. 
7. Micromeritic properties such as tapped density, bulk density, compressibility 
index, angle of repose are also studied. 
8. Release studies: For different type of microspheres are carried out by using 
different suitable dissolution media with and without enzymes.  
9. Magnetic characterization studies: Vibrating Sample Magnetometer (VSM), 
percentage magnetite content determination. 
 
1.5.9  ADVANTAGES OF MAGNETIC MICROSPHERES
9 
1. Avoidance of first pass effect: by minimizing RES clearance. 
2. Increased duration of action: since MM can transit into extra vascular space 
creating an extra vascular depot of drugs for sustained release of drugs within 
the targeted areas. 
3. Controlled and predictable rate of drug release with smaller doses of drug can 
be achieved. Therapeutic response in target organs at only one tenth of free 
drug dose is achieved. 
4. Reduced side effects and reduced toxicity. 
5. Method of preparation is simple. 
6. Ability to bind and release higher concentration of drugs. 
7. It can be injected into the body using hypodermic needle. 
8. In case of tumour targeting, microspheres can be internalized by tumour cells 
due to its much higher phagocytic activity as compared to normal cells. 
INTRODUCTION 
 
Department of Pharmaceutics, Madras Medical College Page 31 
 
9. Problem of drug resistance due to inability of drugs to be transported across the 
cell membrane may be surmounted. 
10. Avoidance of acute toxicity directed against endothelium and normal 
parenchyma cell, controlled release within target tissue for intervals of 30 min 
to 30 h as desired, adaptable to any part of the body. 
 
1.5.10  DISADVANTAGES OF MAGNETIC MICROSPHERES
11
 
1. The drug cannot be targeted to deep-seated organs in the body. 
2. Thrombosis at the site of catheterization. 
3. Unknown toxicity of magnetic beads. 
 
1.5.11  APPLICATIONS
7,9
 
 
1.5.11.1 Clinical Applications 
 It is used as a chemotherapeutic agent. (Loco regional cancer treatment). 
 Magnetic vehicles are used for delivery of therapeutic agent as they can be 
targeted to specific location in the body through the application of magnetic 
field. 
 Magnetic microspheres can be used for stem cell extraction and bone marrow 
purging. 
 Magnetic fluid purging. (Presentation of a new magnetic field therapy system 
for the treatment of  human solid tumors) 
 
1.5.11.2  Biological Applications
14 
 Used in enzyme immobilization-free enzymes are immobilized onto magnetic 
carriers’ surface or porous wall by taking advantage of physical adsorption or 
covalence. Compared with other immobilized carriers, magnetic carriers have 
the following advantages: 
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 Immobilized enzymes are easily separated from the 
products or reactants. 
 The manner of movement of immobilized enzymes can 
be controlled by external magnetic fields, which can 
greatly enhance the catalyzing efficiency of enzyme. 
 Enzyme catalytic reactions can be continuously carried 
out and controlled by a magnetic field in a bioreactor, 
which can reduce the consumption of enzyme. 
 Reutilization of enzyme will reduce the cost. 
 Used for cell isolation, protein purification and targeted 
drugs. 
 Drug discovery, molecular targeting and undergoing the pathway of cell cycle 
regulation. 
 High throughput DNA isolation. (Magnetic bead purification of labelled DNA 
fragments for high throughput capillary electrophoresis sequencing), DNA 
analysis and proteomics. 
 Magnetofection: a methodology based on the association of magnetic 
nanoparticles with gene vectors inorder to enhance gene transfer in the 
presence of a magnetic field. 
 
1.5.11.2 Other Applications 
 
 Non targeted applications of magnetic microparticles include their use as 
contrast agent (MRI). 
 Used as drug reservoirs and in drug transport 
 In hyperthermia. 
 In radionuclide delivery. 
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1. Satinder Kaker et al.14 prepared magnetic microspheres of mesalamine by phase 
separation emulsion polymerisation technique for colon targeting using Eudragit 
S100, Ethyl cellulose and Chitosan polymers. Entrapment efficiency and magnetite 
content by titrimetry was performed. From the in-vitro release study it was observed 
that with increase in drug polymer ratio, particle size increases, thus surface area is 
decreased and release of drug is retarded. Chitosan magnetic microspheres prepared 
by phase separation emulsion polymerisation are found to be the best in all evaluation 
parameters (practical yield, magnetite content, magnetic responsivity, particle size and 
in-vitro release study.     
 
2. Seema Badhana et al.39 prepared colon specific drug delivery of Mesalamine using 
Eudragit S 100- coated chitosan microspheres for the treatment of ulcerative colitis by 
ionic gelation emulsification method using Tripolyphosphate as cross linking agent. 
The microspheres were coated with Eudragit S 100 by the solvent evaporation 
technique. The prepared microspheres were evaluated and the drug release of 
Mesalamine from microspheres was found to decrease as the polymer concentration 
increases. It was observed that Eudragit S 100 coated chitosan microspheres gave no 
release in the simulated gastric fluid, negligible release in the simulated intestinal 
fluid and maximum release in the colonic environment.  
 
 
3. Ahmed Abd El-Bary et al.16 investigated some formulation variables on the 
optimization of pH dependent, colon-targeted, Sustained-release Mesalamine 
Microspheres. The microspheres prepared by O/O emulsion solvent evaporation 
method, employing Eudragit S and hydrophobic pH-independent Ethyl cellulose 
ppolymers. Formulation variables studied included concentration of Eudragit S in the 
internal phase and the ratios between: internal to external phase, drug to Eudragit S 
and Eudragit S to Ethyl cellulose to Mesalamine. Particle size and encapsulation 
efficiency increased by increasing Eudragit S concentration in the internal phase, ratio 
of internal to external phase, and ratio of Eudragit S to the drug. The results was 
showed that microencapsulation of Mesalamine in microspheres using blend of 
Eudragit S and Ethyl cellulose could constitute a promising approach for site-specific 
and controlled delivery of drug in colon. 
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4. Satinder Kakar et al.13 prepared and evaluated magnetic microspheres of 
mesalamine for colon drug delivery. Magnetic microspheres were prepared by solvent 
evaporation technique in the drug polymer ratios 1:1, 1:2, and 1:3 using chitosan  as 
the polymer. The microspheres ere characterised in terms of particle size, percentage 
yield, drug content, encapsulation efficiency, in-vitro release pattern and ex-vivo 
study. 
 
5. Murat Turkoglu et al.114 developed pectin–HPMC compression coated 5-
aminosalicylic acid tablets for colonic delivery. They Prepared 5-ASA core tablets by 
wet granulation method using PVP (K 29-32). Each 100 mg core tablet contained 5-
ASA and was compression coated at 20 kN or 30 kN using 100% pectin, 80% pectin–
20% HPMC and 60% pectin–40% HPMC at two different coat weights as 400 or 500 
mg. Drug dissolution/system erosion/degradation studies were carried out in pH 1.2 
and 6.8 buffers using a pectinolytic enzyme. HPMC addition was required to control 
the solubility of pectin. The optimum HPMC concentration was 20% and such system 
would protect the cores up to 6 h that corresponded to 25–35% erosion and after that 
under the influence of pectinase the system would degrade faster and delivering 5-
ASA to the colon.  
 
6. Josephine leno jenita .J et al.100 Formulated and evaluated the compression coated 
tablets of Mesalazine for colon delivery. In this study, natural polysaccharide; Locust 
bean gum (550,450,350 and 250 mg) are used. The in-vitro release studies carried out 
in 0.1N HCl, Phosphate buffer pH 7.4 and Phosphate buffered saline pH-6.8 
containing 4% w/v of rat caecal contents. These studies proved the Locust bean gum 
can able to protect the core tablet containing Mesalazine under conditions mimicking 
mouth to colon transit and clearly established that Locust bean gum in the form of 
compression coat is a potential carrier for colon targeting. 
 
7. Satinder Kakar et al.38 formulated and evaluated 6-Thioguanine loaded magnetic 
microspheres by continuous solvent evaporation technique inorder to target the 
magnetic microspheres to the cancerous site. The prepared microspheres were 
characterised in terms of percentage practical yield, micromeritic properties, particle 
size, swelling kinetics, magnetic responsiveness, magnetite content and in-vivo drug 
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release study. Swelling kinetics of magnetic microspheres were performed and it was 
found that their swelling rate increased with time. Magnetic content was determined 
by titrimetric method using thiosulphate and potassium iodide for quantitative 
analysis. 
 
8. Vyas M.B et al.28 designed and characterised Cisplatin magnetic microspheres by 
phase separation emulsion polymerisation technique using bovine serum albumin. 
Magnetite was prepared by reacting 10%w/v ferrous sulphate with 20%w/v sodium 
hydroxide solution, followed by washing of the precipitate with dilute ammonia. 
Percentage magnetite content was determined by conventional titrimetric method 
using thiosulphate and potassium iodide for quantitative analysis. It was observed that 
entrapment of magnetite increased with increase in concentration of polymer. The 
maximum magnetite content was found to be 55.48%. In-vitro drug release studies 
shows that the percentage drug release decreased with increase in ratio of polymer 
added. The study is aimed at the overall improvement in the efficacy, reduction in 
toxicity and enhancement of therapeutic index of cisplatin. 
 
9. Liang Guo et al.29     prepared Chitosan Poly(acrylic acid) magnetic microspheres by 
encapsulating dextran coated Fe3O4 nanoparticles into chitosan poly(acrylic acid) 
(PAA) microspheres template and characterized by Transmission Electron 
Microscopy(TEM), Fourier Transform Infrared Spectroscopy (FT-IR), Scanning 
Electron Microscopy (SEM), X-ray powder diffraction (XRD) and Thermogravimetry 
(TG). Water-dispersible superparamagnetic Fe3O4  magnetic nanoparticles with 20-
30nm were prepared by precipitation method in aqueous solution of dextran. The 
chitosan-PAA microspheres were then prepared by polymerizing acrylic acid into 
chitosan template in aqueous solution followed by encapsulation of dextran coated 
Fe3O4 nanoparticles into it by cross-linking with gluteraldehyde. Magnetic properties 
were evaluated from the magnetization curves obtained by vibrating sample 
magnetometer(VSM) and was found that when the magnetic component size of the 
particles is smaller than critical size, the particles will exhibit superparamagnetism. 
The results showed that the formed microspheres demonstrated magnetic behaviour in 
an applied magnetic field. In addition, the magnetite particles were well encapsulated 
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and the composite particles having high magnetite content, which was more than 
40%. 
 
10. Maria Christina Mascolo et al.79 synthesised magnetite nanoparticles using co-
precipitaion reaction at room temperature in the presence of different bases such as 
NaOH, KOH or (C2H5)4NOH. Magnetite shows characteristics of 
superparamagnetism at room temperature and a saturation magnetization (Ms) value 
depending on both the crystal size and the degree of agglomeration of individual 
nanoparticles. The magnetization curve for the synthesised nanoparticles does not 
show any hysteresis behaviour which confirmed that the synthesized particles exhibit 
superparamagnetic properties at room temperature and was found that the Ms value 
decreases as the magnetite particle size decreases. 
 
11. Ling-Han Xiao et al.42 synthesised magnetic-antimicrobial-fluorescent 
multifunctional hybrid microspheres with well-defined nanostructure by the aid of a 
poly(glycidyl methacrylate) (PGMA) template. The magnetic hysteresis loop of the 
M-PGMA/PHGH-CdTe hybrid microspheres displayed a super-paramagnetic 
property, with a saturation magnetization value 4.608emu/g which is sufficient for 
magnetic separation from water solution. This Ms value is less than that of the pure 
magnetic iron oxide nanoparticles (61.87 emu/g), which can be explained by the 
diamagnetic contribution of PGMA template surrounding the magnetic nanoparticles. 
After poly (hexamethylene guanidine hydrochloride) (PHGH) functionalization, the 
resultant microspheres exhibit excellent antibacterial performance. The fluorescent 
feature originating from the quantum dot CdTe endowed the hybrid microspheres 
with targeted localization and biological monitoring functions. 
 
12. Elisangela P. Da Silva et al.43     developed covalent TiO2-co-pectin microspheres 
containing Fe3O4 nanoparticles through an ultrasound-induced crosslinking/ 
polymerization reaction between the glycidyl methacrylate from vinyl groups in TiO2 
and in pectin. The nanostructured pectin microspheres showed an amoxicillin release 
rate slower than that of pure pectin microspheres. The focus of the work was to 
develop a smart biodevice based on magnetic pectin microspheres that shows a 
sustained release profile and further modulated by exposition to a remote magnetic 
field. The cytotoxic concentrations for 50% of VERO cells (CC50) calculated as the 
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concentration required to reduce cell viability by 50% after 72hrs of incubation for 
pectin only microspheres and nanostructured pectin microspheres were 217.7+ 6.5 
and 121.5+ 4.9µgmL
-1
 which showed that the pectin microspheres have great 
pharmacological potential for use in biological environments even after the 
introduction of both Fe3O4 and TiO2. 
 
13. Prabhu Chakkarapani et al.32 developed methotrexate magnetic microcapsules 
(MMC) for targeted rheumatoid arthritis therapy. Methotrexate was loaded into 
CaCO3-PSS (poly(sodium 4-styrenesulfonate)) doped microparticles that were coated 
by layer-by-layer technique. Ferrofluid was incorporated between the polyelectrolyte 
layers. The MMC were evaluated and was found that spherical particles of approx. 
3µm size were obtained with a net zeta potential of +24.5 mV, 56% encapsulation and 
18.6% drug loading capacity, 96% of cumulative drug release obeyed Hixson-Crowell 
model release kinetics. DC magnetization analysis carried out using the vibrating 
sample magnetometer (VSM) technique confirmed the superparamagnetic behaviour 
of the prepared microcapsules. 
 
14. In the website:www.shodhganga.inflibnet.ac.in78 it had been stated that microspheres 
containing magnetite of 20-28% w/w could be effectively targeted at the site by using 
magnet of 5000- 8000 Gauss (Guptha and Hung, 1989). The magnetite content of 
prepared gelatine magnetic microspheres was between 27-29% w/w and was 
sufficient to retain the microspheres at the site of targeting by using a magnet of 8000 
Gauss. It had been proposed that less than 5µm size is used for intravenous route, less 
than 125 µm is used for intra-arterial route and intra-articular route. Particles of this 
size can be administered easily by suspending them in a suitable vehicle and injecting 
them using a conventional syringe with an 18 or 20 gauge needle. The average 
particle size of gelatin microspheres without drug and magnetite was 15.3 µm. 
Incorporation of magnetite to this microspheres increased the average size to 22.5 µm. 
The average particle size of gelatin magnetic microspheres was slightly increased by 
drug loading to around 25-30.6 µm.   
 
15. Naveen K Thakral et al.25 prepared Valdecoxib loaded multiparticulate system to 
achieve site-specific drug delivery to colorectal tumors. Film coating was done with 
the pH-sensitive polymer Eudragit S 100 and sodium alginate was used as 
LITERATURE REVIEW 
 
Department of Pharmaceutics, Madras Medical College Page 39 
 
mucoadhesive polymer in the core. When applied to the mucosal surface of freshly 
excised goat colon, microspheres pretreated with phosphate buffer pH 7.4 for 30 
minutes showed mucoadhesion. The microspheres were found to exhibit slower and 
delayed release and lower intracellular concentration of Valdecoxib.  
 
16. Amol Paharia et al.60 prepared Eudragit coated Pectin microspheres for colon 
targeting of 5-Fluorouracil. Pectin microspheres were prepared by emulsion 
dehydration method using different ratios of drug and Pectin (1:3 to 1:6). Eudragit-
coating of pectin microspheres was performed by oil in oil solvent evaporation 
method using coat:core ratio (5:1) the release profile of Fluorouracil from Eudragit-
coated pectin microspheres was pH dependent. In acidic medium, the release rate was 
much slower; however, the drug was released quickly at pH 7.4. Eudragit-coated 
pectin microspheres are promising controlled release carriers for colon targeted 
delivery of Fluorouracil. 
 
17. Sandeep Kumar et al.22 prepared and evaluate colon specific microspheres of 
Meloxicam. The microspheres were prepared by iontropic gelation method using 
different ratios of Meloxicam and sodium alginate. Eudragit coating of Meloxicam 
sodium alginate microspheres was performed by coacervation phase separation 
technique. The microspheres were characterized by shape, particle size, size 
distribution, incorporation efficiency, in-vitro drug release and stability studies. It is 
concluded from the present investigation that Eudragit coated sodium alginate 
microspheres are promising controlled release carriers for colon-targeted delivery of 
Meloxicam.  
 
18. Josephine Leno Jenita J et al.58 prepared pH sensitive polymer coated micro 
particles containing Curcumin for colon targeting by solvent evaporation technique. 
Eudragit S 100 was selected as a model encapsulation material. The micro particles 
prepared were filled in hard gelatin capsules which were enteric coated with cellulose 
acetate phthalate (CAP) which prevent the burst effect of capsule in acidic pH of 
stomach. The in-vitro release study showed that the drug release was between 
66.12%-71-87% for 10 hours and results indicate that release of drug from 
microspheres followed Fickian diffusion mechanism. 
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19. Kishori L et al.18 formulated Tinidazole microspheres for colon targeted drug 
delivery system by emulsion solvent evaporation method by using Eudragit polymer. 
A 3
2 
factorial design was employed in formulating the microspheres with 
concentration of surfactant (A) and stirring speed (B) as independent variables. The 
particle size and entrapment efficiency were found to be varied by changing various 
formulations parameters like surfactant concentration and stirring speed etc. The 
release profile of Tinidazole from eudragit microspheres was pH dependent. In acidic 
medium, the release rate was much slower, however, the drug was released quickly at 
pH 7.4. It was concluded that eudragit based Tinidazole microspheres offer a high 
degree of protection from premature drug release in simulated upper GIT conditions 
and deliver most of the drug load in the colon and allow drug release to occur.  
 
20. Behin Sundara Raj et al.12 formulated eudragit coated chitosan microspheres of 5-
fluorouracil for colon targeting. Chitosan microspheres were prepared by emulsion-
dehydration method using different rations of Fluorouracil and Chitosan (1:2 to 1:6), 
stirring speed (500-2000rpm) and emulsifier concentrations (0.75% to 1.75% w/v). 
The results showed that the amount of the polymer increased the extent of drug 
release decreased.  
 
21. Dinesh Chandra et al.44 developed multiparticulate system of Eudragit based 
Satranidazole microspheres exploiting pH sensitivity property and specific 
biodegradability for colon targeting. Eudragit S 100 based microspheres were 
prepared by oil-in-oil solvent evaporation method using different drug-polymer ratios 
(1:1 to 1:5), stirring speeds (1400 rpm) and emulsifier concentrations (0.5%-
1.5%w/v). All formulations were evaluated and release profile of Satranidazole from 
Eudragit microspheres was pH dependent. In acidic medium, the release rate was 
much slower; however the drug was released quickly at pH 7.4. The release kinetics 
revealed that drug followed zero order kinetics followed by Higuchi and first order 
model. 
 
22. Rashmi Sareen et al.93 fabricated and characterized solid lipid based microspheres 
(SLM) of Ketoprofen(KPF) by hot melt microencapsulation technique and compared 
its anti-inflammatory potential with the marketed formulation. Results revealed that 
Tween80 resulted in exceptional KPF entrapment efficiency of 82.6% with spherical 
LITERATURE REVIEW 
 
Department of Pharmaceutics, Madras Medical College Page 41 
 
rough surface morphology. The in-vitro drug release showed intial burst release of 
47% upto 2h followed by sustained release of 70% for 12h and was observed that the 
formulations obeyed Higuchi model and Korsmeyer-Peppas model of release kinetics. 
Further in-vitro anti-inflammatory activity by inhibition of albumin denaturation. 
Briefly 1ml sample solution was withdrawn during in-vitro drug release study and 
subjected to anti-inflammatory analysis by adding 1ml of bovine albumin and 
incubated for 30min at 37
0
C after pH adjustment to 6.3 followed by further incubation 
at 57
0
C for 5min. After cooling the turbidity of samples were recorded 
spectrometrically at 660nm. To conclude, SLMs were found to posses superior in-
vitro and in-vivo anti-inflammatory potentials when compared to marketed 
formulation. 
 
23. P. Padmanabhan et al.95   formulated a   herbal preparation (HP-4 of 100mg/10ml 
methanol concentration) using 80% alcoholic extract of leaves of Aloe Vera, Bacopa 
monnieri, Moringa oleifera and rhizome of Zingiber officinale. Different 
concentrations of HP-4 was used to study the in-vitro anti-inflammatory activities in 
terms of effect of hypotonic solution-induced haemolysis on RBC membrane 
stabilization and effect of inhibition of protein denaturation activity using Acetyl 
salicylic acid as the reference drug. In their study, they have stated that “several anti-
inflammatory drugs have shown dose dependent ability to inhibit thermally induced 
protein denaturation. (Grant et al., 1970). Denaturation of proteins is a well 
documented cause of inflammation in conditions like rheumatoid arthritis 
(Mizushima et al., 1964). Thus protection against protein denaturation, which was 
the main mechanism of action of NSAIDs postulated by (Mizushima et al., 1964) 
before the discovery of their inhibitory effect on cyclooxygenase by Vane JR, 1971 
played an important role in the antirheumatic activity of NSAIDs.” It was found that 
HP-4 has dose dependent RBC membrane stabilization and inhibition of protein 
denaturation activity. 
 
24. Ramana G and Krishna Chaitanya A76 prepared and characterised Ethyl cellulose 
coated pectin alginate microspheres of 5-Flurouracil for colon targeting. Pectin 
microspheres were prepared by ionotropic external gelation technique and the drug 
loaded pectin microspheres were coated with Ethyl cellulose to prevent drug release 
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in the stomach and provide controlled dissolution of enteric coat in the small intestine 
and maximum release in the colon. in-vitro drug release  studies were performed in 
conditions simulating stomach to colon transit in the presence and absence of 
pectinase enzyme. The release of drug was found to be higher in the presence of 
pectinase enzyme. The effect of speed of stirred, concentration of polymer and 
reaction time were optimized on the basis of quality of beads and entrapment of 
beads. 
 
25. Hua Zhang et al.98  investigated a multiparticulate system of chitosan hydrogel beads 
for colonic delivery of macromolecules using fluorescein isothicyanate-labelled 
bovine serum albumin as a model protein. The results showed that the hydrogel beads 
were degraded by rat cecal and colonic enzymes, resulting in a marked increase in the 
release of protein which indicated the potential of the multiparticulate system to serve 
as a carrier to deliver macromolecules specifically to the colon. In their study, they 
utilized a commercially available almond emulsin beta-glucosidase preparation 
capable of degrading chitosan and that mimicked the degradation function of rat cecal 
and colonic enzymes in-vitro (Zhang and Neau, 2001) for checking the possibility of 
employing the enzyme preparation as a standardized in-vitro system to substitute for 
microbial enzymes to limit animal use for assessing the suitability of chitosan based 
formulations for colon targeting was tested. 
 
26. R. Mazumder et al.102 designed ethyl cellulose coated 5-flourouracil loaded pectin 
microspheres for colon targeting. The pectin microspheres were prepared by 
ionotropic-external gelation technique and ethyl cellulose coating was given by co-
acervation phase separation method and characterization was performed by testing the 
entrapment efficiency, particle size, micromeritic properties, in-vitro release 
behaviour, SEM, FT-IR
 
etc.
  
In-vitro drug release study was performed in the presence 
of pectinase enzyme (Pectinex ultra SPL) which contains different pectinolytic and 
cellulolytic enzymes (endo-poly-galacturonase, endo-pectinylase and pectin esterase), 
and other activities such as ß-galactosidase, chitinase and transgalactosidase. 
 
27. Bala Venkata Pradeep.V et al.11 developed enteric coated pectin matrix tablets of 
Metronidazole for colon targeting. Matrix tablets were prepared by mixtures of pectin, 
a hydrophilic swellable polymer, in which the drug was dispersed. Eudragit S 100 
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used as a pH sensitive polymer for coating the matrix tablet. The drug release studies 
were performed by presence and absence of pectinolytic enzymes. The matrix tablets 
in presence of pectinolytic enzymes, undergoes a faster erosion process which, in 
agreement with the results of release studies, resulted in a more marked increase in 
drug release rate. Comparison of results obtained in the presence and absence of 
pectinolytic enzymes showed pectin was the most interesting candidate for colonic 
delivery and most susceptible to enzymatic degradation, thus assuring a greater site- 
specificity of drug release. From curve fitting the drug release showed good 
correlation coefficients (R values) for Korsmeyer-Peppas equation. The n value was 
found to be in between 0.85-1.26. The values are closer to 1 and hence it is concluded 
that the drug release was more dependent on the effect of polymer relaxation.  
 
28. KC Ofokansi et al.63   formulated and evaluated Gluteraldehyde-crosslinked Chitosan 
microparticles for the delivery of Ibuprofen, by using glueraldehyde saturated toluene 
(GST) as the cross-linking agent. The swelling behaviour of the particles and 
ibuprofen release were assessed in both simulated gastric fluid without pepsin (ph 1.2) 
and simulated intestinal fluid without pancreatin. Results have shown – Entrapment of 
Ibuprofen in gluteraldehyde-cross-linked Chitosan microparticles can be exploited to 
target and control the release of the drug and possibly reduce its gastro-erosive side 
effects. 
29. Surender Verma et al.91  formulated, evaluated and optimized osmotically controlled 
colon targeted drug delivery system, using microbially triggered  and osmotically 
controlled approach,using Prednisolone as model drug for treatment of inflammatory 
bowel disease (IBD). Prednisolone-beta-cyclodextrin complex was prepared and 
phase solubility study was carried out. The formulations containing PEG was found to 
be promising drug delivery system better release kinetics. 
 
30. Gurunath.S.Padaonkar et al.51  have formulated and evaluated of oral novel colon 
targeted drug delivery system using natural polymers. This was used using pectin as 
carrier and Olsalazine sodium as model drug. The tablets were coated with inulin 
followed by shellac and were evaluated for average weight, hardness and coat 
thickness. The study revealed that polysaccharides as carriers and inulin and shellac 
as coating material can be used effectively for colon targeting of both water soluble 
and insoluble drugs . 
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31. Morusu Keerthana et al..86 formulated and evaluated the Secnidazole colon targeting 
drug layered pellets. Secnidazole is used in treatment of Amoebiasis. The main 
objective is formulation of Secnidazole pellets by using power layering technique. 
Evaluation of prepared pellets can be performed by using parameters such as angle of 
repose, bulk density, carr’s index and percentage drug release. By observing the 
percentage drug release studies of 5% and 10% concentration the 4 polymers one can 
conclude that the Eudragit  RSPO 5% showed the better release compared to all other 
formulations. 
 
32. Sheth Zankhana et al.69 designed and developed 5-fluorouracil loaded biodegradable 
microspheres. The present study is aimed at the overall improvement in the efficacy, 
reduction in toxicity and enhancement of therapeutic index of 5-fluorouracil, by using 
solvent evaporation technique, by using polymethacrylate polymers like Eudragit 
L100,eudragit S100, eudragit P4135F and methylcellulose. Stabilty studies revealed 
that 4degree Celsius is the most suitable temperature for storage of 5-Fluorouracil. 
Overall, this study showed that the 5-fluorouracil can be formulated in a 
microparticulate drug delivery system by using various polymers and it showed 
significant prolonged drug release. 
 
33. N. Najmuddin et al.65 formulated and done in-vitro evaluation of floating 
microspheres of Ketoprofen prepared by emulsion solvent diffusion method using 
Eudragit S100 and Eudragit L100 polymer. The short half life of ketoprofen and 
multiple administration dose make ketoprofen a very good candidate for formulation 
of floating drug delivery system. Results show that as increase in drug: polymer ratio 
affects the particle size, percentage yield, in-vitro buoyancy and drug release of 
microspheres. The data obtained in this study thus suggest that a floating 
microspheres of ketoprofen are promising for sustained drug delivery which can 
reduce dosing frequency. 
 
34. Pornsak Sriamornsak et al.83 have done swelling and erosion of pectin matrix 
tablets and their impact on drug release behaviour. The matrix tablets were prepared 
by direct compression using different types of pectin. swelling and erosion studies 
were carried out in various media. The pectin matrix tablets formed a continuous gel 
layer while in contact with the aqueous media undergoing a combination of swelling 
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and erosion .The extent of matrix swelling, erosion and diffusion of drug determined 
the kinetics as well as mechanism of drug release from pectin-based matrix tablets . 
The findings were attributed to the effect of swelling and erosion on the drug release 
from hydrophilic matrix tablets, which is an interesting way of formulating oral 
sustained/controlled–release matrix tablets using a process that is easy and 
inexpensive and does not require special production equipment . 
 
35. Ranjit Singh.20 Formulated and evaluated the colon targeted delivery system for 
Nitrofurantoin using guar gum as carrier. When studies were continued in colon 
fluids, matrix tablets released almost 100% drug. The results of the study show that 
matrix tablets containing 20% guar gum are most likely to provide targeting of 
Nitrofurantoin in the colon. 
 
36. Erxi Che et al.88 have developed phosphonate–terminated magnetic mesoporous 
silica nanoparticles for pH-controlled release of doxorubicin and improved tumor 
accumulation. Phosponate–terminated magnetic mesoporous nanoparticles was 
designed by incorporating MNPs in the centre of mesoporous silica nanoparticles and 
followed by grafting phosphonates group on the surface of MMSNs. The results can 
open the possibilities for combining magnetic targeting drug delivery system and pH-
responsive release of doxorubicin to cancerous tissues. 
 
37. Heming Huang et al.81 have done Mossbauer spectroscopy of protein-passivated iron 
oxide nanoparticles using uncoated and bovine serum albumin (BSA-)passivated 
magnetic iron oxide particles. Coating with BSA does not influence the particle 
morphology and does also not affect the magnetite to maghemite ratio. 
 
38. Meltum Cetin et al.64  have prepared and characterized the anti cancer drug–loaded 
implantable PLGA ( poly lactide –co-glycolide ) microparticles. PLGA microparticles 
loaded with doxorubicin HCL (DOX) were prepared via o/w emulsion solvent 
evaporation. DOX-loaded PLGA microparticles displayed a significant cytotoxicity 
towards the RG2 cells as compared to the unloaded PLGA microparticles. This work 
can be considered for further studies on evaluation of the in-vivo efficacy and the 
brain’s regional distribution of DOX-loaded PLGA microparticles using mature male 
Sprague-Dawley rats. 
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39. Nitesh Shah et al.21 have designed, developed and optimized colon-targeted drug 
delivery system for Crohn’s disease. The aim of the present investigation was to 
develop double coated systems comprising of pH independent (Eudragit RS100) and 
pH dependent coatings (Eudragit S100) of polymethacrylates for delivery of 
metronidazole exclusively to the colon. Metronidazole colon targeted tablets prepared 
in the present work by double coating method. Optimization of coating levels of both 
the coats using central composite design reveals that the polymer concentration and 
coating level plays a significant role in the drug release property of which coating 
level of Eudragit RS was more significant after the tablet reaches colon. Thus 
proposed system may be successfully used for colon targeting of Metronidazole. 
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3.1 AIM OF THE WORK: 
  Mesalamine (5- amino salicylic acid) is an anti-inflammatory drug used for the first 
line treatment of Inflammatory Bowel Diseases (IBD); namely Ulcerative Colitis (UC) and 
Chron’s Disease (CD). 
The aim of the present study is: 
 To formulate Magnetically Responsive Mesalamine Microspheres by solvent 
evaporation method by using biodegradable polymers Chitosan and Pectin 
with an intention to produce a depot near the target organ and drug delivery 
utilizing the principle of magnetic targeting. 
  To carry out the various pharmaceutical and magnetic characterizations and 
thereby to optimize the formulation and to study the effect of polymer type on 
in- vitro drug release  
 To carry out the in-vitro release studies using microflora activated system. 
 To carry out the in-vitro anti-inflammatory activity by inhibition of protein 
denaturation method. 
The main objective of the study is to localize the drug only at the target site and thereby 
minimizing the dose and drug induced toxicity.  
 
3.2 PLAN OF THE WORK:  
  
The present study was designed and planned as follows:  
 
1. Literature Survey or Review of Literature 
2. Preformulation studies 
 FTIR study- Identification and Compatibility of drug and excipients. 
3. Standard Curve for Mesalamine in Phosphate Buffer Saline pH 7.4. 
4. Formulation and Development 
 Chemical synthesis of the magnetic carrier – Magnetite (Fe3O4). 
 Formulation of Magnetically Responsive Microspheres of Mesalamine using 
biodegradable polymers (Chitosan and Pectin) in different drug-polymer  
ratios. 
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5. Evaluation studies of Magnetic Microspheres 
5.1 Physicochemical Characterization 
 Surface morphology  
 Mean Particle Size  
 Drug Excipient Interaction – FT-IR 
5.2 Pharmaceutical Characterization 
 Percentage Yield 
 Drug content (%) 
 Drug Loading (%) 
 Swelling Kinetics 
 Evaluation of Flow Property  
 in-vitro drug release study of Microspheres 
 Study of effect of polymer type on in- vitro drug release 
 Release kinetics of the optimized formulation  
 Stability Studies of the Optimized formulation- at ambient conditions and 
accelerated conditions as per the ICH guidelines 
 
5.3 Preclinical in-vitro Screening Studies 
 in-vitro release study of optimized formulation  using microflora activated 
system 
 in-vitro anti-inflammatory activity of optimized formulation 
 
5.4 Magnetic Characterization 
 Magnetite Content Determination 
 Magnetic Separation Behaviour 
 Magnetism Assesment using VSM 
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4. RATIONALE OF THE STUDY 
Irritable Bowel Diseases (IBD) are the chronic idiopathic multi-factorial 
inflammatory diseases of gastrointestinal tract, which mainly include two forms; Ulcerative 
Colitis (UC) and Chron’s Disease (CD).15 
IBD which has been ranked 5
th
 among the most prevalent gastro intestinal diseases 
and if left untreated posses a high risk to develop as colon cancer.
15
 IBD can affect  a person 
of any age and can continue throughout their life as it does not have any permanent cure. 
Treatment objectives are: 
1. Reduction in drug related side effects by employing site-specific local targeting. 
2.  Improve the quality of life. 
 
4.1 RATIONALE FOR SELECTION OF DRUG  
 
Small intestine and large intestine or colon are the main regions involved in IBD, 
marked by chronic inflammation in specific mucosal or transmural locations as a result of an 
immune reaction of the body against its own intestinal tissue
15
.  
 
The available conventional dosage forms are not effective in the treatment of this 
colonic disease as dosing frequency is quite high which leads to many adverse effects. Drug 
delivery systems for treating the colonic disorders such as IBD are failing as the drugs do not 
reach the site of action in appropriate concentration. Thus, there is a need to develop effective 
and safe therapy for the treatment of these colonic disorders, using site- specific targeted drug 
delivery approach.  
 
The drug of choice, Mesalamine is an intestinal anti-inflammatory drug, amino 
salicylic acid derivative. It acts by reducing inflammation of colon topically by inhibiting the 
production of IL-1 and TNF-α, inhition of the lipoxygenase pathway, scavenging of free 
radicals and oxidants, and inhibition of NF-ҝB.15 Mesalamine undergoes extensive first pass 
metabolism. Adult dose is about 800 mg two- three times a day for total of 2.4 g/day. Thus, 
the development of site-specific targeted drug release to colon would be clearly 
advantageous.
73
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4.2  RATIONALE FOR SELECTION OF POLYMER 
10,88,62,63,67
 
Chitosan and Pectin are biodegradable polymers which undergo enzymatic 
degradation in colon resulting in drug release in colonic pH. When combined with the 
principle of magnetic carrier technology, these polymeric carriers act as a smart biodevice for 
site specific colon targeted drug delivery.
10
 Both these polymers used in different ratios are 
cheap, non toxic, biocompatible and have controllable biologic activity. 
 
4.3 RATIONALE FOR SELECTION OF MAGNETIC CARRIER
10
 
  
In this study, ferric oxide (Fe2O3) is used as the preferred magnetic carrier because of its 
non-toxicity, superparamagnetism (for magnetite particles below 30-40 nm),
49 
high level of 
accumulation in tissues, interruption of  magnetization  when the magnetic field is removed, 
and biocompatibility due to high affinity for water which allows to interact with biological 
species.
10 
  
4.4  RATIONALE FOR SELECTION OF DOSAGE FORM
43,16
  
 
Upon oral administration, 5-ASA exhibits rapid and nearly complete absorption from 
the upper intestine, resulting not only in systemic side effects but also in lowering the dose 
reaching the colon with the subsequent decreased probability of therapeutic success.
92 
Drug delivery systems based on microparticles sensitive to a remotely applied 
magnetic field appear on the top of the (bio) technological innovations, because the magnetic 
field, if used in a therapeutic level, does not affect biological tissues.
10 
The present study is to formulate Magnetically Responsive Mesalamine Microspheres 
which offers a localized drug delivery only at the target site by the combined effect of 
physical approach (utilizing the principle of magnetic targeting with an intention to produce 
a depot near the target organ) and biochemical approach (using biodegradable polymers 
chitosan and pectin for drug release in a controlled manner).
17
 By producing a depot near the 
target organ, unwanted distribution of drug to non target organ can be avoided. This approach 
will localize the drug only at target site and minimize the dose and drug induced toxicity. 
5. DISEASE PROFILE 
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5.1 DISEASE PROFILE  
5.1.1 Irritable Bowel Disease (IBD)
 15,23,43,50,79
 
Irritable Bowel Diseases (IBD) are the chronic idiopathic multi-factorial inflammatory 
diseases of gastrointestinal tract, which mainly include two forms; Ulcerative Colitis (UC) 
and Chron’s Disease (CD). Small intestine and large intestine or colon are the main regions 
involved in IBD, marked by chronic inflammation in specific mucosal or transmural locations 
as a result of an immune reaction of the body against its own intestinal tissue.  
 
Figure 14: Chron’s Disease & Ulcerative Colitis 
Depending on the location of disease, UC can be further classified as
43 
 Ulcerative Proctitis (disease only in rectum)  
 Limited or Distal Colitis (disease in the left side of the colon)  
 Pancolitis (disease in the entire colon). 
 Proctosigmoiditis 
            
Figure 15: Types of Ulcerative Colitis 
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Accounting for far fewer cases are the other forms of IBD: 
 Collagenous Colitis 
 Lymphocytic Colitis 
 Ischaemic Colitis 
 Diversion Colitis 
 Behcet’s Colitis 
 Indeterminate Colitis 
5.1.2 Incidence and Prevalence
15
  
 Irritable Bowel Disease is becoming a global disease because of high incidence and 
prevalence of it with respect to time. IBD occupied 5
th
 rank among the most prevalent 
gastrointestinal diseases and if left untreated posses a high risk to develop as colon cancer.
25
 
It has been estimated that upto 2,40,000 people in U.K, 2.2 million in Europe and 1.4 million 
in United States are suffering from IBD, among which, 100,000 are children. There are very 
lower incidences in Asia, Africa and South America. Peak incidences occur in young people 
between 15–40 years of age. In general IBD can affect a person of any age and can continue 
throughout their life as it does not have any permanent cure. 
 
5.1.3 Etiology of IBD
15
  
 The etiology of IBD is unknown. There are three interrelated factors thought to be 
affect symptoms to varying degrees:  
 Gut factors  
 Environmental factors  
 Genetic factors  
 
5.1.3.1   Gut factors 
 Dysregulation of immune system: It leads to excessive immune response to 
normal microflora and epithelial cell abnormalities. Changes in the 
composition of gut microflora facilitate abnormal inflammatory responses. 
 Microbial infections: Mycobacterium paratuberculosis, measles virus and 
bacterial flora have been suggested as possible causes of CD. 
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 Impaired epithelial barrier function: It leads to abnormal intestinal 
permeability which further results in 
 Impaired gene expression: by enhanced apical expression of transferring 
receptor proteins in enterocytes in inflammatory mucosa of IBD patients. 
5.1.3.2   Environment factors 
 Smoking: The risk of developing CD is high in smokers.  
 Oral contraceptives: There may be a slight association between oral 
contraceptive use and the development of CD. 
 Diet: Diet high in fat and sugars, Stress etc may also contribute to IBD. 
 
5.1.3.3  Genetic factors 
  
 Family history: One in five people with IBD have a first-degree relative 
(parent, child or sibling) with the disease. 
 Race and ethnicity: UC is more common among whites than in non-whites..it 
also occurs mostly in Caucasians. There is also evidence for ethnic aggregation 
(higher in Jewish decent). 
 Genes linked to IBD: recently, the first gene associated with CD, the NOD2 
was identified. 
 
Figure 16: Colon affected by Chron’s Disease & Ulcerative Colitis                                            
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Ulcerative Colitis versus Crohn’s Disease 
The basic distinction between UC and CD are location and severity. However, some 
patients with early stage IBD have features and symptoms of both disorders (called 
indeterminate colitis). In general, UC is a local inflammatory bowel disorder in which 
continuous mucosal inflammation extends from the rectum towards the cecum, and is 
generally associated with excess IL-13 production whereas, CD is a relapsing inflammatory 
disorder which may involve any part of the GIT but more pronounced in ileocecal region 
which is generally associated with excess production of IL-2/IL-23 and IFN-γ/IL-17. These 
Inflammatory Bowel Diseases have been linked with an increased risk of colorectal cancer. 
Table: 6 Comparison of Crohn’s vs. Ulcerative Colitis15 
S.No Features Ulcerative Colitis Crohn’s Disease 
1 Site of action 
 
Extending from rectum 
proximally to entire colon only 
 
Any part of GIT (mainly 
ileum is involved) 
2 Symptoms 
 
Diarrhea, weight loss, 
malnutrition and other 
extraintestinal manifestations, 
smoking improves condition 
Diarrhea, abdominal pain, 
weight loss, growth failures in 
kids, smoking worsens the 
condition 
3 
Pathology and 
complications 
Mucosal inflammation, if get 
severe can cause colon cancer. 
Fistulas, abscesses and 
strictures absent 
 
Transmural inflammation, non 
caseating granuloma, fistulas, 
abscesses, perianal 
involvement and strictures are 
common, toxic megacolon 
absent 
4 
Cytokine 
response 
Associated with Th17 
 
Associated with Th2 
5 Distribution Continuous distribution Discontinuous 
6 Drugs used 
 
5-ASA, Sulfasalazine, 
Balsalazide, Infliximab, 
Azathioprine and 
mercaptopurine 
 
Hydrocortisone, Budesonide, 
Prednisolone, Sulfasalazine, 
Olsalazine, Mesalazine and 
Balsalazide, Infliximab 
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5.1.4   SYMPTOMS AND COMPLICATIONS
43 
Intestinal 
 Abdominal cramps and pain 
 Bloody diarrhoea 
 Severe urgency to have a bowel movement 
 Fever 
 Loss of appetite, Weight loss, Anaemia (due to blood loss) 
Intestinal complications of IBD includes: 
 Profuse bleeding from the ulcers. 
 Perforation (rupture) of the bowel. 
 Strictures and obstruction: more common in persons with CD. 
 Fistulae and perianal disease: more common in persons with CD. 
 Toxic megacolon: this life-threatening complication of UC requires surgery 
 Colorectal cancer: there is high risk of colon cancer in patients with UC. 
Chronic inflammation generated by the production of reactive oxygen species 
leads to generate dysplasia, which further develops into  CAC, i.e., colitis 
associated colorectal cancer, which is a severe form of ulcerative colitis. 
 
Extraintestinal 
Persons with IBD may have 
 Arthritis  
 Osteopenia (low bone density), Osteoporosis (bone loss) 
 Impaired skeletal and groth development in children due to malabsorption and 
malnutrition. 
 Liver and kidney disorders 
 
5.1.5  PATHOPHYSIOLOGY 
15,79
 
Multiple etiologies have been proposed for IBD, but the precise cause is unknown. 
When a luminal antigen crosses the epithelial layer, T- lymphocytes (helper cells and 
cytotoxic cells) are activated. These t-cells are normally found in gut wall but in IBD, the 
normal regulation of their activity is disturbed. Helper T-cells, type-1 (Th-1), are associated 
principally with CD, whereas Th-2 cells are associated principally with UC.  
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Figure 17: Pathophysiology of IBD 
  In UC, with the influx of neutrophils in lamina propia, there is localized collection of 
pus cells surrounded by inflamed tissues and causes depletion of mucin. Activation of 
mucosal inflammatory cells also leads to the production of large number of inflammatory 
mediators such as cytokines, leukotrienes, prostaglandins, platelet activating factor, oxygen 
radicals, thromboxanes, proteases etc. which are atleast partly responsible for tissue damage. 
 
In CD, the accompanying inflammation is described as irregular/ patchy, segmented, 
and transmural. Most commonly, terminal ileum exhibits early lesions on or near Peyer’s 
patches.
15
  
 
5.1.6   MAJOR CHALLENGES IN THE TREATMENT OF IBD
15 
 
Cure of UC depends on severity of disease its subtypes and its pre-existing illness. 
Long term medication produces lot of side effects such as  peptic ulcers, diarrhea, 
nephrotoxicity and hepatotoxicity, glaucoma, vomiting, Cushing’s syndrome etc., which 
negatively affects the quality of life of UC suffered patients. 
 
Major challenge in the treatment of UC is the reduction in drug related side effects by 
employing site specific local targeting. 
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5.1.7   TREATMENT OF IBD 
15,23
                  
Most treatments for IBD are either medical or surgical. Surgery is typically used only 
if all the medical options have failed. The goal of medical treatment in IBD is to suppress the 
abnormal inflammatory response. This allows the intestinal tissue to heal, relieving the 
symptoms of diarrhea and abdominal pain. The recommended first-line therapy for the 
treatment of active symptoms, induction of remission and maintenance of remission in 
patients with mild to moderate UC is the anti-inflammatory agent 5-aminosalicylic acid (5-
ASA). 
Pharmacological therapy includes: 
 Aminosalicylates 
 Corticosteroids  
 Immunosupressants 
 Anti-tumor necrosis factor (TNF) agents and  
 Antibiotics. 
 Table: 7   Drugs used for the treatment of Ulcerative colitis
15 
S. 
No 
Classes of drugs 
 
Trade 
name 
Marketed 
formulations 
Adverse effects Dose 
1 Aminosalicylates 
 
Sulfasalazine 
 
 
Azulfidine 
Delayed release 
tablet 
Agranulocytosis, 
panceatitis, intestinal 
nephritis 
4-6g/day 
divided qid 
Mesalamine Asacol 
Eudragit S100 
coated tablet 
(dissolves at      
pH 7) 
 
Hepatits, male infertility, 
arthralgia, pneumonitis, 
loss of apetite, stomach 
upset, blurred vision 
 
 
2-4g/day 
divided qid 
Balsalazide Colazal Tablet 
Head ache, abdominal 
pain, stomach pain, 
stomach upset, diarrhea, 
vomiting, joint pain. 
 
 
1.5-3g/day 
divided qid 
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2 Corticosteroids 
Budesonide Entocort 
Eudragit L 
coated beads 
 
Dry or irritated mouth or 
throat,cough, painful 
speech, neck pain, 
stomach pain 
 
 
Prednisolone 
Deltasone, 
Orasone 
 
Tablets of 
2.5,5,10,20 and 
50mg and oral 
solutions/ syrups 
 
Hyperglycaemia, 
hypertension, electrolyte 
disturbances 
5-50mg/ day 
Dexamethasone 
Dexasone, 
diodex, 
decadron 
Tablets, elixirs 
and solutions 
Cataract, 
osteoporosis,myopathy 
Tablets 
0.25-6mg 
, Elixir 
0.5mg/ml, 
Solution 
0.5,1mg/5ml 
3 Immunosupressants 
Azathioprine, 
Methotrexate 
Imuran, 
Rheumatrex, 
Traxell 
Tablet, Solution 
given i.v 
 
Hyperglycaemia, 
hypertension, electrolyte 
disturbances, cataract 
 
50mg 
25mg/ml 
4 Antimicrobials 
Metronidazole Flagyl 
 
Extended release 
tablets 750mg, 
capsule 375mg, 
cream 0.75 %and 
1% injections 
 
Utricaria, glossitis,long 
term use may develop 
paresthesia 
750mg 
orally tid  
for 5- 10 
days 
Ciprofloxacin 
Cipro, 
Proquin XR 
Tablets 250,500 
and 750mg, 
Extended release 
(XR) 500 & 
1000mg, 
injections 
200mg/100ml 
 
Diarrhea, vomiting  and 
rash. Other side effects 
(e.g. head ache, 
abdominal pain, 
cardiovascular, 
gastrointestinal, etc.)in 
less than 1% of the 
patients 
500mg 
twice daily 
5 
Anti-TNF agents 
 
Infliximab Remicade  
Powder for 
intravenous 
injection 
Acute infusion reactions 100mg 
  
          
Adalimubab Humira 
Prefilled glass 
syringe 
 
Serum sickness, increase 
in sepsis, pneumonia, 
tuberculosis etc. 
 
20mg/ 0.4 
ml 
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5.1.8   DIAGNOSTIC PROCEDURES
43 
To help confirm diagnosis of CD or UC, one or more of the following tests and 
diagnostic procedures may be performed. 
 
Figure 18: Diagnosis of IBD 
 Blood tests: the presence of inflammation in the body can be identified by 
the abnormal levels of red and white blood cells, platelets and C-reactive 
protein (CRP). 
 Stool tests: it checks for signs of inflammation in GIT as well as 
infections. 
 Endoscopic procedures: includes Flexible sigmoidoscopy and 
colonoscopy. 
 External imaging procedures: e.g. computerized tomography (CT) scans 
and magnetic resonance imaging (MRI). 
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6.1 MESALAZINE
32,79,109 
  Mesalazine is an intestinal anti-inflammatory drug, amino salicylic acid 
derivative, used in the treatment of ulcerative colitis. It acts by reducing  inflammation of 
colon topically by preventing production of substances involved  in inflammatory process 
such as arachidonic acid.  
6.1.1   PHYSIOCHEMICAL PROFILE: 
Chemical Structure 
 
Molecular Formula   : C7H7NO3 
Molecular Weight   : 153.1 
Chemical Name   : 5-Amino-2-hydroxybenzoic acid 
CAS     : 89-57-6 
Category    : Gastrointestinal Agents, Anti ulcer 
Description     : white or light grey or light pink powder or crystals. 
Solubility      : Very slightly soluble in water, practically insoluble in               
   alcohol. It dissolves in dilute solutions of alkali      
   hydroxides and in dilute hydrochloric acid. 
TAXONOMY 
 
Kingdom  : Organic Compounds 
Super Class  : Benzenoids 
Class  : Benzene and substituted derivatives 
Sub Class  : Benzoic acids and derivatives 
Direct Parent  : Aminobenzoic acids 
Melting Point    : 275-280
o 
C . 
Packing and Storage   : in an airtight container, protected from light.  
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6.1.2   PHARMACOKINETIC PROFILE 
23,59,109
 
ABSORPTION      5-ASA undergoes a complete systemic absorption 
within the proximal intestine when administered in an 
unformulated fashion, leaving little or no 5-ASA to treat 
the colon. Mesalamine is quickly metabolized by N-
acetyl-transferase 1 to N-acetyl-5-ASA within intestinal 
epithelial cells and the liver. Oral bioavailability: 20-
30% is absorbed; 10-35% absorbed in the colon. 
 
DISTRIBUTION  About 80% of N-Acetyl-5-amino salicylic acid is bound 
to plasma proteins, whereas 40% of mesalamine is 
protein bound and the volume of distribution data is not 
available. 
 
METABOLISM  Rapidly and extensively metabolized, mainly to N-
acetyl-5-ASA (Ac-5-ASA) in the intestinal mucosal 
wall and the liver. Ac-5-ASA is further acetylated 
(deactivated) in at least 2 sites, the colonic epithelium 
and the liver.  
 
EXCRETION     It is extensively metabolized in the liver and it is 
excreted in the urine and faeces as either unmetabolized 
5-ASA or N-acetyl-5-ASA. The half-life of mesalamine 
is dose-dependent and reaches up to 1.4 h while the 
half-life of N-acetyl-5ASA reaches up to 6 h. 
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6.1.3  PHARMACOLOGICAL PROFILE 
 
MECHANISM OF ACTION   Although mesalamine is a salicylate, its therapeutic 
effect does not appear to be related to cyclooxygenase 
inhition; possible mechanism of action by inhibition of 
the production of IL-1 and TNF-ἀ , inhition of the 
lipoxygenase pathway, scavenging of free radicals and 
oxidants, and inhibition of NF-ҝB. Specific mechanism 
of action of this drug have not been identified.
15
  
INDICATION AND USAGE: 
 Used in the treatment of Inflammatory Bowel Diseases such as 
 Ulcerative colitis (mild to moderate) 
 Crohn’s disease  
 
DOSAGE (FOR ADULTS):  
 
Controlled release tablets  :  PO 800 mg tid for total of 2.4 g/day for 6 week.  
Suppositories :  PR 500 mg suppository bid for up to 6 week. Retain          
  suppository in rectum for 1–3 hr or more to achieve  
  maximum benefit. 
Suspension Enema : PR 4 g in 60 ml as rectal instillation qid  for up to 6 week,  
  preferably at bedtime, retained for 8 hr. 
 
SIDE EFFECTS:  
 
Cardio vascular : Chest pain.  
CNS : Headache; asthenia; dizziness; fever; sweating; malaise. 
DERM : Acne; itching; rash.  
EENT : Rhinitis; sore throat; pharyngitis.  
GI : Abdominal pain; cramps; discomfort; colitis exacerbation;           
  constipation; diarrhoea; dyspepsia; vomiting; flatulence; nausea  
RESP : Cough.  
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PRECAUTION:  
 
Pregnancy : Category B. 
Lactation :  Excreted in breast milk.  
Children : Safety and efficacy not established.  
Intolerance and colitis exacerbation:  
  Some patients develop acute intolerance syndrome or exacerbation of colitis 
characterized by cramping, acute abdominal pain, bloody diarrhoea etc. Symptoms generally 
abate when mesalamine is discontinued.  
CONTRAINDICATION:  
 Hypersensitivity to salicylates 
OVERDOSE:  
In case of overdose atrioventricular block, cardiac arrest paralysis of respiratory     
center may occur. The treatment is symptomatic. 
DRUG INTERACTIONS: 
Reduced absorption of digoxin has been reported when administered concomitantly 
with Mesalamine.   
BRAND NAMES:  
 Asacol   by Win-Medicare Limited 
Pentasa -500 by Ferring Pharmaceuticals 
5A by Wallace Pharmaceuticals Ltd. 
Mesacol (80mg)   
Mesacol Suppos.  by Sun Pharmaceuticals 
Mesacol Enema   
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7.1 CHITOSAN
48,66 
    Nonproprietary Names  BP: Chitosan Hydrochloride 
 PhEur: ChitosaniHydrochloridum 
 
Synonyms    2-Amino-2-deoxy-(1,4)-ß-D-glucopyranan;                 
deacetylated chitin; deacetyl chitin; ß-1,4-poly-D- 
glucosamine; poly-D-glucosamine; poly-(1,4-ß-D-
glucopyranosamine).      
Chemical Name    Poly-ß-(1,4)-2-Amino-2-deoxy-D-glucose. 
 
Empirical Formula &  Chitosan is chitin deacetylated to form soluble. 
Molecular Weight    Mol. Wt: 10,000 – 10,00,000. 
 
Description Chitosan occurs as odorless, white or creamy-white 
powder or flakes. Fiber formation during precipitation 
(cottonlike chitosan). 
Moisture content Adsorbs moisture from the air, the amount depends on 
the initial moisture content, temperature and relative 
humidity. 
Solubility  Sparingly soluble in water; practically insoluble in 
ethanol (95%), other organic solvents and neutral or 
alkali solutions at pH above 6.5. dissolves readily in 
dilute and conc. solutions of most organic acids and to 
some extent I  mineral inorganic acids. 
 
Functional Category Coating agent; disintegrant; film-forming agent; 
mucoadhesive; tablet binder; viscosity-increasing agent. 
 
Applications in Chitosan is used in cosmetics and is under investigation  
Pharmaceutical Formulations  for use in drug delivery applications like controlled drug 
delivery, mucoadhesive dosage forms, rapid release 
dosage forms, improved peptide delivery, colonic drug 
delivery. 
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7.2 PECTIN
48,66 
 
Nonproprietary Names  USP: Pectin 
 
Synonyms    Citrus Pectin; E440; methopectin; methyl    
pectinate; mexpectin; pectin; pectinic acid  
 
Chemical Name Pectin. 
 
Description Pectin is a high molecular weight, carbohydrate- like 
plant constituent consisting primarily of chains of 
galacturonic acid units linked as 1,4-a-glucosides. 
 
Molecular Weight    Mol. Wt: 30,000 – 1,00,000. 
 
Description    Pectin occurs as a coarse or fine, yellowish- white,   
 odorless powder that has a mucilaginous taste.  
 
Solubility     Soluble in water;  insoluble in ethanol (95%) and other   
organic solvents  
 
Functional Category   Adsorbent; emulsifying agent; gelling agent;thickening   
agent; stabilizing agent. 
 
Applications in    Pectin is used as an adsorbent, bulk forming agent and 
Pharmaceutical Formulations emulsion stabilizer. Pectin gel beads have been shown  
to be effective for controlling the release of a drug 
within  the GIT. It is used in colon- biodegradable 
pectin matrix with a pH-sensitive polymeric coating, 
which retards the onset of drug release, overcoming the 
problems of pectin solubilityin the upper GIT. Pectin-
based matrices with varying degrees of esterification as 
oral controlled- release tablets. 
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7.3  FERROUS SULPHATE
32,72 
IUPAC Name   Iron(II) sulphate
 
 
Synonyms    Green vitriol, Iron vitriol, Copperas, Melanterite,      
Szomolnokite 
 
Chemical  Formula& CAS No FeSO4.7H2O  [7782-63-0] 
 
      
 
 Molecular Weight & Density 278   [1.895g/cm
3
] 
 
Melting Point    333 – 337 K 
 
Description Blue-green crystals or light green, crystalline powder; 
odorless, efflorescent in air. On exposure to moist air, 
the crystals rapidly oxidize and become brown.   
Solubility     Soluble in water (29.51 g/100ml at 25
0
 C);  
insoluble in alcohol. 
Vapor Pressure    1.95 kPa 
Magnetic susceptibility(χ)  1.12x10-2 cm3/mol  
Refractive Index (ηD)   1.471     
Functional Category  Haematinic 
Dose  Prophylactic, 300mg; therapeutic 600 to 900mg daily, 
in divided doses. (300mg of ferrous sulphate is 
approximately equivalent to 60 mg of ferrous iron). 
 
EXCIPIENT PROFILE 
 
Department of Pharmaceutics, Madras Medical College Page 72 
 
7.4  SODIUM HYDROXIDE
48 
Nonproprietary Names                     BP:    Sodium Hydroxide 
JP:   Sodium Hydroxide 
USP-NF:  Sodium Hydroxide 
PhEur:  Sodium Hydroxide 
 
 
Synonyms    Caustic soda, E524, lye, soda lye, sodium hydrate 
 
Chemical Name & CAS Sodium hydroxide   [1310-73-2]           
 
Empirical Formula &  NaOH 
Molecular Weight    Mol. Wt: 40.00 
 
Description Sodium hydroxide occurs as white or nearly white fused 
mass, available in small pellets, flakes or sticks, hard 
and brittle and shows a crystalline fracture, very 
deliquescent and on exposure to air it rapidly absorbs 
carbondioxide and water.     
Typical Properties    Acidity/ alkalinity  
pH approx. 12 (0.05% w/w aqueous solution) 
pH approx. 13 (0.5% w/w aqueous solution) 
pH approx. 14 (5% w/w aqueous solution) 
 
Functional Category   Alkalizing agent, buffering agent 
 
Applications in    It is widely used to adjust pH of solutions. It can also  
Pharmaceutical Formulations  be used to react with weak acids to form salts. 
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7.5  MAGNESIUM STEARATE
48 
Nonproprietary Names                       BP:    Magnesium Stearate 
JP:  Magnesium Stearate 
USP-NF: Magnesium Stearate 
PhEur:  Magnesii Stearas 
 
Synonyms Magnesium octadecanoate; octadecanoic acid;    
magnesium salt; stearic acid. 
Chemical Name & CAS  octadecanoic acid magnesium salt.  
 
Empirical Formula & C 36H 70MgO4 
Molecular Weight  591.34 
 The USPNF describes magnesium stearate as a  
 compound of magnesium with a mixture of solid  
 organic acidsthat consists chiefly of variable  
 proportion of magnesium stearate and magnesium  
 palmitate. The PhEur 2005 describes it as amixture of  
 magnesium salts of different fatty acids chiefly stearic  
 and palmitic acids and in minor proportions of other  
 fatty acids. 
Description  It is a very fine, light white, precipitated or milled, 
  impalpable powder of low bulk density, having a faint  
  stearic acid odour and a characteristic taste. It is  
  greasy to touch and readily adheres to skin.  
Solubility      It is practically insoluble in ethanol, ether and water;  
      slightly soluble in warm benzene. 
 Functional Category Tablet and capsule lubricant. 
 
Applications in  It is widely used in cosmetics, food and  
Pharmaceutical Formulations pharmaceuticals It is primarily used as a lubricant in  
 capsule and tablet manufacture.   
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7.6  LIQUID PARAFFIN
48 
    Nonproprietary Names                     BP:    Light Liquid Paraffin 
JP:   Light Liquid Paraffin 
USP-NF:  Light Mineral Oil 
PhEur:  Paraffin, Light Liquid  
 
Synonyms    Light white mineral oil 
Chemical Name  Light  mineral oil       
Empirical Formula  It is a mixture of refined liquid saturated hydrocarbons 
obtained from petroleum. It is less viscous and has a 
lower specific gravity than mineral oil 
Molecular Weight     
Description Light mineral oil is a transparent, colorless liquid, 
without fluorescence in daylight. It is practically 
tasteless and odorless when cold, and has a faint odor 
when heated.   
 
Typical Properties    Soluble in chloroform, ether and hydrocarbons, 
sparingly soluble in ethanol; practically insoluble in 
water. 
 
Functional Category Emollient; oleaginous vehicle; solvent; tablet and 
capsule lubricant; therapeutic agent. 
 
Applications in    It is widely used to adjust pH of solutions. It can also  
Pharmaceutical Formulations  be used to react with weak acids to form salts. 
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8. MATERIALS AND METHODS 
8.1 MATERIALS USED IN FORMULATION 
 The list of drugs and excipients, their manufacturer and use in the present study are 
shown in Table 8 
Table 8- List of drug(s) and excipients 
Name of the material Name of the company 
 
Use in the formulation 
 
Mesalamine IPCA Laboratories, MP 
 
Active Ingredient 
 
 
Chitosan 
 
Sigma Aldrich Biodegradable polymer 
Pectin 
HiMedia Laboratories Pvt. 
Ltd, Mumbai 
 
Biodegradable polymer 
 
Magnesium Stearate MMC Health care, Chennai 
 
Droplet stabilizer 
 
Talc MMC Health care, Chennai 
 
Stabilizing agent 
 
Liquid Paraffin 
Microfine Chemicals, 
Chennai. 
 
Dispersion phase 
 
Sodium Hydroxide IRP, Chennai 
 
Reagent 
 
Ferrous Sulphate 
 
Microfine Chemicals, 
Chennai 
 
Reagent 
 
 
Tween 80 
 
Supra Chemicals, Chennai Emulsifier 
 
Span 80 
 
Supra Chemicals, Chennai Emulsifier 
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Bovine albumin 
 
Supra Chemicals, Chennai Reagent 
 
ß-glucosidase 
 
Synkromax, Chennai Enzyme preparation 
 
Pectinase 
 
Synkromax, Chennai Enzyme preparation 
Potassium dihydrogen 
ortho Phosphate 
Supra Chemicals, Chennai 
 
Reagent 
 
Disodium hydrogen 
phosphate 
Supra Chemicals, Chennai 
 
Reagent 
 
 
Sodium chloride Supra Chemicals, Chennai 
 
Reagent 
 
 
 
Hydrochloric acid 
 
Supra  Chemicals, Chennai Reagent 
Glacial acetic acid Supra Chemicals, Chennai 
 
Solvent 
 
 
Dist. Water 
 
Supra Chemicals, Chennai Solvent 
 
Gluteraldehyde 
 
Microfine Chemicals, 
Chennai 
Cross linking agent 
 
Toluene 
 
Supra Chemicals, Chennai Solvent 
 
n-Hexane 
 
Supra Chemicals, Chennai Solvent 
 
Span 80 
 
Microfine Chemicals, 
Chennai 
Emulsifier 
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8.2 EQUIPMENTS 
 Table 9- Equipments used in the formulations and evaluation of Microspheres 
Name of the equipment Name of the company 
High Speed Homogenizer 
 
Remi, India 
 
 
Centrifuging Machine 
 
MC Dalal, Chennai. 
 
Electronic Balance 
 
MC Dalal, Chennai. 
 
UV Spectrophotometer 
 
Shimadzu, Japan 
 
Optical Microscope 
 
Focus Trademark, India 
 
Binocular Microscope 
 
Olympus, India. 
 
SEM Analyser 
 
Hitachi, Japan 
 
FT- IR Spectrophotometer 
 
Nicolet, India 
 
Dissolution Apparatus 
 
Campbell, India 
 
 
Vibrating Sample Magnetometer 
 
 
Lakeshore, USA 
 
 
BOD Incubator 
 
CDS Lab, Ambala Cantt 
 
Stability Chamber 
 
REMI CHM-6-plus 
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8.3 PREFORMULATION STUDIES
11,24
 
 The preformulation studies are the first step in the rational development of any 
formulation. It can be defined as “investigation of physical and chemical properties of drug 
substance alone and combined with the excipients. “The overall objective of preformulation 
testing is to generate information useful to the formulator in developing stable and 
bioavailable dosage forms that can be mass produced. 
 The goals of the study are: 
 To establish physical characteristics. 
 To establish its compatibility with the excipients. 
 To determine kinetic rate profile. 
8.4   DRUG-POLYMER INCOMPATIBILITY STUDIES 
8.4.1 Fourier Transform Infra-Red Spectroscopy
24,34
 
 The compatibility between pure drug and polymer was detected by FT- IR spectra 
obtained. 1-2mg of Mesalamine alone, mixture of drug and excipients were weighed and 
mixed properly with Potassium bromide uniformly. The spectra’s were recorded over the 
wave number 4000- 500cm
-1
. 
 
Table 10- Composition of drug and excipients for FTIR spectra 
S.No. Ingredients 
1 Drug alone 
2 Drug & Chitosan 
3 Drug & Pectin 
4 Drug & Magnetite 
5 Drug & Magnesium stearate 
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8.5   CALIBRATION CURVE FOR MESALAMINE
53,86 
 
8.5.1 Preparation of Phosphate Buffer Saline (PBS) pH 7.4
32 
 Dissolve 2.38g of disodium hydrogen phosphate, 0.19g of potassium dihydrogen 
phosphate and 8.0g of sodium chloride in sufficient water to produce 1000ml. Adjust the pH, 
if necessary. 
8.5.2   Preparation of 0.1N Hydrochloric acid (pH 1.2)
32 
8.5ml of conc. HCl was dissolved in 1000ml of distilled water. Adjust pH, if necessary.
 
8.5.3 Standard Curve in Phosphate Buffer Saline pH 7.4
32,53,86
 
 100 mg of Mesalamine was transferred into a volumetric flask and dissolved in 15ml 
of 0.1N hydrochloric acid and the volume was made up to 100ml with PBS pH 7.4. The 
resulting solution was labeled as stock solution 1. From this stock solution, 10ml was taken 
and diluted to 100ml with Phosphate buffer saline pH 7.4 was labeled as stock 2. From this 
stock solution, 4ml, 8ml, 12ml, 16ml, 20ml, 24ml and 28ml were pipetted out into separate 
standard flasks and made up to 100ml with Phosphate buffer saline pH 7.4. The absorbance 
of solution is measured at 230nm using UV- Visible Spectrophotometer. The calibration 
curve was then plotted taking concentration on X- axis and absorbance on Y- axis.  
 
8.6   PREPARATION OF MESALAMINE MAGNETIC MICROSPHERES 
 
8.6.1  Preparation of Magnetite
28 
  The magnetite (Fe3O4) was prepared by reacting 10%w/v ferrous sulphate 
(containing 5%  tween 80) with 20%w/v sodium hydroxide solution, followed by washing of 
the precipitate with dilute ammonia inorder to get magnetite free of sulphate ions. This 
precipitate of magnetite was then dried at 100
0
C and passed through sieve no.300. 
 
8.6.2  Preparation of  Gluteraldehyde saturated toluene (GST)
63 
 Gluteraldehyde (100ml) and toluene (100ml) were placed in a beaker and stirred at 
1000rpm for one hour using a magnetic stirrer. Then the solvent mixture was kept overnight 
for stabilization after which the upper toluene layer saturated with gluteraldehyde was 
decanted and used as gluteraldehyde saturated toluene (GST).  
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8.6.3  Preparation of Mesalamine Magnetic Microspheres
,17,24,33
 
 
Magnetic microspheres of Mesalamine was prepared by O/O solvent evaporation with 
chemical cross linking method. Accurately weighed quantity of polymer  was dissolved in 
10ml of 1% glacial acetic acid and accurately weighed drug was dissolved in minimum 
quantity of 0.1N  HCl  and added  into the polymer solution.10mg of  magnesium stearate 
was then added to the polymer-drug solution. Finally, specified amount of magnetite was 
added to this solution. The organic phase was drop-wise to 30ml of liquid paraffin containing 
2% Span 80 and stirred at a speed of 1500rpm at 80
0
C using high speed homogenizer. 
Stirring was continued for 1 h after the complete addition of polymer drug solution into oil. 
After 1 h stirring, 1-2 ml of  GST was added dropwise to the mixture with continuous stirring 
at 500 rpm for the next 1 h at a temperature 50-55
0 
C. Stirring was stopped after 1 h of  
addition of GST. Suspension of microspheres in paraffin oil thus obtained was centrifuged 
and the clear supernatant was decanted. Microspheres were then filtered and washed 3 times 
with hexane to remove liquid paraffin and  then with distilled water to remove unentrapped 
drug from the surface of  the microsphere. After that the microspheres were air dried and 
stored in dessicator at room temperature. 
 
Table 11: Formulation of  Mesalamine Magnetic Microspheres 
Form
ulatio
n 
code 
Dru
g 
(mg) 
Polymer 
(mg) 
Magn
etite 
(mg) 
Magnesiu
m 
Stearate 
5% 
(mg) 
Liq. 
para
ffin 
(ml) 
Span 
80 
(ml) 
Drug: 
Polymer 
ratio 
  Chitosan Pectin      
F1 125 125 - 50 10 30 0.6 1:1 
F2 84 166 - 50 10 30 0.6 1:2 
F3 63 187 - 50 10 30 0.6 1:3 
P1 125 - 125 50 10 30 0.6 1:1 
P2 84 - 166 50 10 30 0.6 1:2 
P3 63 - 187 50 10 30 0.6 1:3 
Q1 125 62.5 62.5 50 10 30 0.6 1:1 
Q2 84 42 83 50 10 30 0.6 1:2 
Q3 63 31 94 50 10 30 0.6 1:3 
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8.7 EVALUATION OF MAGNETIC MICROSPHERES
68
 
8.7.1  PHYSICOCHEMICAL CHARACTERIZATION
33 
8.7.1.1 Shape and surface morphology studies using Scanning Electron Microscope
33
 
The shape and surface morphology of  magnetic microspheres were investigated using 
scanning electron microscopy (SEM). The samples for SEM study were prepared by lightly 
sprinkling the formulation on a double-adhesive tape stuck to an aluminum stub. The stubs 
were then coated with gold to a thickness of ~300 Å under an argon atmosphere using a gold 
sputter module in a high vacuum evaporator. The coated samples were then randomly 
scanned and photomicrographs were taken with a scanning electron microscope.
 
 
8.7.1.2 Particle Size Analysis
24,38,60
  
 The average particle size of the prepared mesalamine magnetic microspheres for 
intra-arterial administration was measured by optical microscopy using a calibrated Eye piece 
micrometer and was compared to that of microspheres without drug and also with those 
microspheres prepared without drug and magnetite. The average size of 100 particles was 
determined by the equation.  
 
Size of individual particle (μm) = Number of divisions on eye piece × Calibration factor  
Average Particle Size (μm) = 
Sum of Size of Individual Particles 
Number of particles 
 
8.7.1.3 Drug- Excipient Interaction
24,34
 
 The FT-IR spectrum was recorded on Shimadzu FT-IR spectrophotometer, for the 
prepared mesalamine magnetic microspheres. The samples were prepared by grinding 
samples (5mg) with KBr (100mg) and then pressing the mixtures into pellets, further placed 
on a crystal sample holder and scanned from 4000cm
-1
 to 400cm
-1
. 
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8.7.2  PHARMACEUTICAL CHARACTERIZATION 
8.7.2.1 Percentage Yield
38
  
 Microspheres were weighed and the percentage yield was calculated by taking into 
consideration the total weight of the drug and excipients used for preparation of 
microspheres. 
Percentage Yield = 
Practical yield 
X 100 
Theoretical yield 
 
8.7.2.2  Estimation of Drug Content and Entrapment Efficiency
24,28,33
 
 50mg of microspheres was weighed and dissolved in 2.5ml of 0.1N HCl and suitably 
diluted with phosphate buffer saline pH 7.4 in 50 ml standard flask. The solution was kept for 
24hrs and filtered to separate the fragments. Drug content was analyzed after suitable dilution 
by UV spectrophotometer at a wavelength of 230 nm against phosphate buffer saline pH 7.4 
as blank. The drug content of each formulation was calculated using the following equation 
Percentage Drug 
Entrapment Efficiency = 
Actual Drug Content 
X 100 
Theoretical Drug Content 
  
8.7.2.3 Drug Loading Capacity
100
 
 Drug loaded microspheres were mixed in 2.5ml of 0.1N HCl and suitably diluted with 
phosphate buffer pH 7.4 at room temperature and kept for 24 h. After filtration and suitable 
dilution, Mesalamine   present in the solution was determined.  
% Drug Loading = 
Quantity of the drug present in the microspheres  
X 100 
Weighed quantity of microspheres 
 
8.7.2.4 Swelling studies
33,38,63
 
  The degree of swelling of the microspheres was investigated in PBS pH 7.4 without 
enzymes. A dialysis membrane 9 cm long was activated by immersion in 50ml of distilled 
water regulated at 90
0
C for 1 h and then washed with distilled water. A known weight of 
microspheres was placed in the activated dialysis membrane which was tied at both ends and 
immersed in a beaker placed on a thermostated bath maintained at 37
0
C. At fixed intervals, 
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the membrane was removed from each medium, dried with filter paper and weighed. The 
degree of  swelling (H) was calculated using the formula: 
 
  H  = 
Final weight of microspheres- Initial weight of microspheres           
Initial weight of microspheres 
 
8.7.2.5  EVALUATION OF FLOW PROPERTIES
18,38,39,100
 
   
Flow properties of microspheres were investigated by determining the following standard 
procedures.  
8.7.2.5.1 Bulk Density 
 Bulk density was determined taking a known weight of dried microspheres in a 
measuring cylinder and tapping 3 times from 1 inch height at 2 second interval. The bulk 
volume is noted and the bulk density was calculated from the following equation. 
  
Bulk Density = 
Weight of microspheres 
Bulk volume of microspheres 
8.7.2.5.2 Tapped Density 
 Tapped density is the ratio of mass of microspheres to the volume occupied by the 
same mass of the powder after a standard tapping of a measure. Weighed quantity of 
microspheres was taken in a cylinder and tapping 300 times from 1 inch at 2 second interval. 
The tapped volume is noted and the tapped density was calculated from the following 
equation. 
Tapped Density = 
Weight of microspheres 
Tapped volume of microspheres 
 
8.7.2.5.3 Hausner’s Ratio  
 
 Hausner’s ratio is used for predicting the flow characteristics. 
 
Hausner’s ratio = 
Tapped density 
Bulk density 
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8.7.2.5.4 Compressibility Index  
 
 Compressibility index was determined using bulk density and tapped density. 
 
Compressibility index (%) = 
Tapped density – Bulk density 
X 100 
Tapped density 
 
8.7.2.5.5 Angle of Repose 
A funnel was fixed to a stand and the bottom of the funnel was fixed at a height of 3 
cm from the plane. Microspheres were placed in funnel and allowed to flow freely and the 
height and radius of the heap of microspheres was measured. 
    tan θ = h/r 
Where, ‘h’ is the height of heap and 
 ‘r’ is the radius of heap of microspheres 
 
Table 12: Standards for Pre-compression Characteristics 
Compressibility 
Index (%) 
Hausner’s 
Ratio 
Angle of 
Repose 
(degrees) 
Type of flow 
<10 1.00-1.11 25-30 Excellent 
11-15 1.12-1.18 31-35 Good 
16-20 1.19-1.25 36-40 Fair 
21-25 1.26-1.34 41-45 Passable 
26-31 1.35-1.45 46-55 Poor 
32-37 1.46-1.59 56-65 Very poor 
>38 >1.60 >66 Very very poor 
 
 
8.7.2.6  in- vitro Drug Release Study
24,115
  
The in- vitro drug release study was carried out in basket apparatus using a mixture of 
45ml of 0.1N HCl  and 855ml of  PBS pH 7.4 as the dissolution medium maintained at  
37
0
C+ 0.5
0
C. Weighed microspheres containing 50mg of drug were introduced into the 
dissolution medium. Aliquots were taken at regular time intervals and after suitable dilution, 
percentage drug release analysed by UV Spectrophotometer at 230nm. 
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8.7.2.7   RELEASE KINETICS OF THE OPTIMIZED FORMULATION
37,45
 
 The in- vitro release data for the optimized batch was fitted to various release kinetic 
models (Zero-order, First- order, Higuchi, Hixon- Crowell and Korsmeyer- Peppas models). 
The goodness of fit was found out to describe the kinetics of drug release. 
8.7.2.7.1 Zero order release model 
 Zero order models describe the systems where the drug release rate is independent of 
its concentration of the dissolved substance. 
   C = Ko t 
Where, C- Cumulative percentage drug released 
    Ko – zero-order constant 
  t- time 
A plot of time on x- axis and cumulative percentage drug released on y-axis gives a 
straight line with slope, Ko if it follows zero-order Kinetics. 
Application: This relationship can be used to describe the drug release of several types of 
modified release pharmaceutical dosage forms like trans-dermal systems, matrix tablets with 
low soluble drugs in coated forms and osmotic systems. 
 
8.7.2.7.2 First order release model 
 First order models describe the systems where the release rate is dependent on the 
concentration of the dissolved substance. 
  Log C = log Co – K t / 2.303   
Where, C – Cumulative percentage drug remaining 
  Co- Initial concentration of drug 
  K – First order constant 
 A plot of time on x-axis and log cumulative percentage drug remaining on y – axis 
gives a straight line with slope, K / 2.303 if it follows first- order kinetics. 
Application: This relationship can be used to describe the drug dissolution in pharmaceutical 
dosage forms containing water –soluble drugs in porous matrices. 
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8.7.2.7.3   Higuchi release model 
 The Higuchi model describes the release from systems where the solid drug is 
dispersed in an insoluble matrix and the rate of release is related to the rate of drug diffusion. 
    Q = K √t  
Where, Q – Cumulative percentage drug released 
             K- Constant reflecting the design variables of the system 
   t – Time 
 A plot of square root of time on x-axis and cumulative percentage drug released on y-
axis gives a straight line if it follows Higuchi Kinetics. 
Application: This relationship can be used to describe the drug dissolution from several 
types of modified release pharmaceutical dosage forms like some trans-dermal systems and 
matrix tablets with water soluble drugs. 
8.7.2.7.4   Hixson-Crowell release model 
 The Hixson-Crowel cube root model describes the release from systems where there 
is a change in surface area and diameter of the tablets or particles.  
 Qo
1/3
 – Qt1/3 = K HC K t  
Where, Qt – Cumulative percentage drug released in time t 
Qo – initial amount of the drug 
KHC – the rate constant for Hixson-Crowell rate equation 
K – Constant incorporating the surface volume relation 
A  plot of time on x-axis and cube root of cumulative percentage of drug remaining on 
y-axis gives a straight line if it follows Hixson-Crowell kinetics. 
Application: This equation applies to dosage forms like tablets, where the dissolution occurs 
in planes that are parallel to the drug surface if the tablet dimensions diminish proportionally, 
in such a manner that the initial geometrical form keeps constant.  
8.7.2.7.5 Korsmeyer and Peppas Model:  
 Korsmeyer and Peppas Model derive a simple relationship which describes the drug 
release from a polymeric system. 
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     Mt / Mα = K t 
n
 
Where, Mt / Mα – fraction of drug released at time t 
   K - Release rate constant 
    n - Release exponent 
A plot of log time on x-axis and log cumulative percentage of drug released on y-axis 
gives a straight line, if it follows Korsmeyer and Peppas kinetics. 
 
DIFFUSION 
COEFFICIENT 
OVERALL SOLUTE 
RELEASE MECHANISM 
EFFECT ON DRUG
11
 
RELEASE 
0.45 Fickian diffusion 
Only due to diffusion 
through the matrix 
0.45<n<0.89 
Anamolous  
(non-fickian diffusion) 
Drug diffusion and polymer 
relaxation (erosion) 
0.89 Case-II transport Only due to polymer 
relaxation (erosion) n>0.89 Super case-II transport 
 
In-vitro drug release data were fitted to various models such as zero- order, first- 
order, Higuchi equation, Korsmeyer- Peppas equation, and Hixson-Crowell equation to know 
about the mechanism of drug release: 
1. C versus t (zero order) 
2. log C versus t (first order) 
3. Q versus square root of t (Higuchi) 
4. Qt versus cube root of t (Hixson-Crowell) 
5. log% Qt versus log t (Korsmeyer- Peppas) 
8.7.2.8   Stability Studies
28,45,108 
 
Of the prepared microspheres, the formulation with optimum percentage drug release 
was selected for stability studies. The optimized formulation was placed  separately in 
borosilicate screw capped glass containers  in  Stability chamber at a temperature of 40±2°C / 
75±5% RH (climatic zone IV conditions for accelerated testing) and  at ambient room 
temperature and humidity for a period of 60 days. The samples were assayed for drug content 
at regular intervals of 15
th
, 30
th
 and 60
th
 day.    
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8.7.3   PRECLINICAL in-vitro SCREENING STUDIES 
8.7.3.1  in- vitro Drug Release Study in Microflora Activated System 
89,96,98,102.
 
Identification of an enzyme system that can simulate polysaccharide degradation in 
the colonic environment would be beneficial for a more mechanistic investigation. 
Commercially available ß-glucosidase preparation has the ability to degrade chitosan due to 
an existing chitinase in the enzyme. Similarly commercially available pectinase enzyme 
preparation has the potential to degrade pectin polymer. Therefore, such a mixture of enzyme 
preparation was used as one of the release media for the evaluation of in- vitro drug release 
study of optimised formulation .This study aims in investigating  the possibility of its use as  
an  in-vitro enzyme system to substitute for rat cecal and colonic enzymes and thereby 
limiting animal use in the initial screening study for such polymer-based colon delivery 
systems. 
8.7.3.2   in- vitro Anti-inflammatory activity screening
85,93 
in- vitro anti-inflammatory activity screening
  
has been carried out for optimized 
formulation as a pre stage for in-vivo animal studies 
Inhibition of albumin denaturation
 
 1 ml sample solution was withdrawn every one  hour during in- vitro drug release 
study and thereafter, subjected to in- vitro anti-inflammatory analysis. Equal volume of 
distilled water was used for the purpose of control. To each reaction mixture, 1 ml of bovine 
albumin (1% in distilled water) was transferred and pH was adjusted to 6.3 by using small 
amount of 1 N HCl, Samples were incubated for30 min at 37
0
 C in the dark followed by 
incubation at 57
0
C for 5 min. Reaction tubes were then cooled under running tap water and 
turbidity of all the samples were recorded spectrophotometrically at 660 nm. Percentage 
inhibition of albumin denaturation was calculated by using the formula: 
 
Percentage inhibition = 
Abs Control- Abs Sample 
X 100 
Abs Control 
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8.7.4   MAGNETIC CHARACTERIZATION
 
8.7.4.1.1 Preparation of 0.1N Sodium Thiosulphate
32 
Dissolve 25 g of sodium thiosulphate and 0.2 g of sodium carbonate in carbondioxide-
free water and dilute to 1000ml with the same solvent. 
8.7.4.1.2 Standardization of 0.1N Sodium Thiosulphate
32 
 Dissolve 0.200 g of potassium bromate, weighed accurately, in sufficient water to 
produce 250 ml. To 50 ml of this solution add 2 g of potassium iodide and 3 ml of 2 M HCl 
and titrate with the sodium thiosulphate solution using starch solution, added towards the end 
of titration, as indicator until the blue colour is discharged. 
1 ml of 0.1 M sodium thiosulphate is equivalent to 0.002738 g of KBrO3. 
 
8.7.4.1.3 Determination of magnetite content
28,24,78,38
  
  Magnetite(Fe3O4) content in the prepared magnetically responsive 
microspheres was determined by the conventional titrimetric method using thiosulphate and 
potassium iodide for quantitative analysis. An accurately weighed amount of magnetic 
microspheres (after destruction by gentle heating) was dissolved in mixture of water (200ml) 
and conc. HCl (200ml) by heating it to the boiling point. After boiling for 15s, the solution 
was cooled rapidly. Then 3 g of  potassium iodide was added and kept in dark for 15min, the 
liberated iodine was then titrated with 0.1 N sodium thiosulphate using starch as indicator. 
Similarly a blank titration was carried out. The difference between titrations gave the amount 
of iodine liberated by ferric ion. 
Each ml of   0.1 N sodium thiosulphate is equivalent to 0.005585 g of ferric ion. 
 
Percentage Magnetite Content = 
(Blank- Titre value) x Equivalent factor x 
(Estimated molarity/ Expected  molarity)  
Weight taken (equivalent to magnetite) 
 
 
 
x 100 
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8.7.4.2  Magnetic Separation Behaviour 
42 
 
 The formulated magnetic microspheres were dispersed in water to study their 
magnetic separation behavior. The magnetic microspheres were made to  move towards the 
direction of magnetic field in an aqueous solution under the externally applied magnetic field 
in 30s. After the ceassation of external magnetic field, the microspheres  were checked for 
even spread out in water again with bottle shaking. 
 
8.7.4.3  Magnetism Assessment using Vibrating Sample Magnetometer (VSM)
29,32,42 
 
 Magnetic properties of microspheres containing magnetite were characterized via 
vibrating sample magnetometry. The VSM operates on the principle that when a sample 
material is placed in a uniform magnetic field, a dipole moment proportional to the product of 
the sample susceptibility times the applied field is induced in the sample. The sample also 
undergoing sinusoidal motion induces an electrical signal which is proportional to the 
magnetic moment, vibration amplitude and vibration frequency. 
 
In single domain materials there is little or no hysteresis and the magnetic particles 
reach saturation faster compared to a multi domain material. If the sample contains multiple 
domains, a hysteresis loop in the magnetization curve is observed. This hysteresis from multi 
domain formation would cause a decrease in the response of the system.
30
    
  
 The magnetization curves of the magnetically responsive microspheres were taken at 
room temperature using Vibrating Sample Magnetometer (VSM) to study the super-para 
magnetic behavior by finding the saturation magnetization value.  
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9. RESULTS AND DISCUSSION 
9.1 PREFORMULATION STUDIES
 
 9.1.1 Drug- Polymer Compatibility Studies using FTIR Spectroscopy
24,34 
 The compatibility between drug and polymer was confirmed by using FTIR 
spectroscopy. 
 Infrared spectroscopic analysis for drug (Mesalamine), Polymers (Chitosan, 
Pectin),magnesium stearate and  Drug-Polymer mixture were carried out. 
 The principal IR peaks of pure  Mesalamine and polymers Chitosan and Pectin are 
shown in table 13-16 and figure 19-22. 
Figure 19:  FTIR spectra of (Mesalamine + Chitosan) Vs. Mesalamine 
Table 13: FTIR spectra of  (Mesalamine + Chitosan) Vs. Mesalamine 
 
  
Wave Number (cm
-1
) Interpretation 
2800-2900 
O-H streching of  
carboxylic acid 
3000-3050 Ar-H stretching 
1550-1600 C=C stretching 
3600-3700 Phenolic O-H stretching 
1680-1700 
C=O stretching of  
carboxylic acid 
3300-3450 N-H stretching 
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Inference: 
 The FTIR study revealed that there is no interaction between the drug and polymer, 
since the major peaks of the drugs are not affected by the excipients 
     
 
 
 
 
 
 
 
 
 
Figure 20: FTIR spectra of (Mesalamine + Pectin) Vs. Mesalamine 
Table 14: FTIR spectra of(Mesalamine + Pectin) Vs. Mesalamine 
Wave Number (cm
-1
) Interpretation 
2800-2950 
O-H streching of  
carboxylic acid 
3000-3050 Ar-H stretching 
1550-1600 C=C stretching 
3600-3700 Phenolic O-H streching 
1680-1700 
C=O stretching of  
carboxylic acid 
3200-3400 N-H streching 
   
Inference: 
 The FTIR study revealed that there is no interaction between the drug and polymer, 
since the major peaks of the drugs are not affected by the excipients 
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Figure: 21 FTIR spectra of (Mesalamine + Magnetite) Vs. Mesalamine 
 
Table 15: FTIR spectra of ( Mesalamine + Magnetite) Vs. Mesalamine 
Wave Number (cm
-1
) Interpretation 
2900-2950 
O-H streching of 
carboxylic acid 
3000-3050 Ar-H stretching 
1500-1600 C=C stretching 
3500-3700 Phenolic O-H streching 
1680-1700 
C=O stretching of 
carboxylic acid 
3200-3300 N-H streching 
   
Inference: 
 The FTIR study revealed that there is no interaction between the drug and polymer, since 
the major peaks of the drugs are not affected by the excipients. 
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Figure: 22 FTIR spectra of(Mesalamine + Magnesium Stearate) Vs. Mesalamine 
 
Table 16: FTIR spectra of (Mesalamine + Magnesium Stearate) Vs. Mesalamine 
Wave Number (cm
-1
) Interpretation 
2800-2900 
O-H streching of  
carboxylic acid 
2950-3050 Ar-H stretching 
1490-1550 C=C stretching 
3500-3700 Phenolic O-H stretching 
1680-1700 
C=O stretching of  
carboxylic acid 
3300-3400 N-H stretching 
Inference: 
 The FTIR study revealed that there is no interaction between the drug and polymer. 
Hence it can be concluded that the major peaks of the drugs are not affected by the excipients.
 29 
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9.2 STANDARD CALIBRATION CURVE FOR MESALAMINE
32,53,86 
 The UV Spectrophotometric method was used to analyze Mesalamine. The absorbance of 
the drug in phosphate buffer saline (pH 7.4) was measured at a wavelength of 230nm. The results 
are given in table 17 and figure 23. 
             Table: 17  Standard Curve for Mesalamine 
S.No. 
Concentration 
(µg/ml) 
 
Absorbance (nm) 
1. 0 0 
2. 2 0.132+0.0043 
3. 4 0.248+ 0.0187 
4. 6 0.375+ 0.0533 
5. 8 0.488 +0.0305 
6. 10 0.612+ 0.0489 
*Mean+SD(n=3) 
 
 
Figure 23: Standard Curve for Mesalamine in PBS pH 7.4 
 
Inference  
 As shown in figure the linearity was exhibited at a concentration range of 0- 10 µg/ml 
of Mesalamine. It obeys Beer-Lambert’s law.53,86 
y = 0.0608x + 0.0052 
R² = 0.9996 
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9.3 EVALUATION OF MICROSPHERES 
9.3.1 PHYSICOCHEMICAL CHARACTERIZATION33 
9.3.1.1 Scanning Electron Microscopy
33
 
 Morphological analysis of the microspheres was carried out using Scanning 
Electron Microscopy and the result is shown in figure 24.   
 
Figure 24: SEM Photographs of  (a) Optimized formulation 
Inference    
 The SEM photograph reveals that the microspheres were discrete and spherical in 
shape.                       
9.3.1.2 Mean Particle Size by Microscopy
24,38 
The particle size of various formulations of microsphere were determined by binocular 
microscopy.  The results of mean particle size are depicted in the table 18 and figure 26.  
 
Figure 25:  Photograph of Optimized formulation 
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Table 18: Mean Particle Size of Microspheres 
Formulation code Mean Particle Size(µm) 
F1 34.95 
F2 41.55 
F3 41.70 
P1 42.30 
P2 45.15 
P3 47.85 
Q1 33.30 
Q2 36.30 
Q3 36.60 
 
  
     
 
Figure 26: Mean Particle size of Microspheres 
 Inference  
 The data revealed that average particle size of microspheres increased with increasing 
polymer concentration. Higher concentration of polymer produced a more viscous dispersion 
with larger droplets and consequently larger microspheres were formed.
44,60,100
The particle 
size of microspheres was found in the range of 33.3 to 47.85 µm.  
  
  In general, less than 5µm size is used for intravenous route, less than 125 µm is used 
for intra-arterial route. Particles of this size can be administered easily by suspending them in 
a suitable vehicle and injecting them using a conventional syringe with an 18 or 20 gauge 
needle.
78
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9.3.1.3 Drug  Excipient Interaction 
24,34
 
 
 
 
 
 
 
 
 
  
  
 Fig 27: FT-IR Spectra of Optimized formulation 
 Table 19: FT-IR Spectra of Optimized formulation 
Wave Number (cm
-1
) Interpretation 
2900-3000 
O-H streching of  
carboxylic acid 
2900-3000 Ar-H stretching 
1550-1600 C=C stretching 
3500-3700 Phenolic O-H stretching 
1650-1750 
C=O stretching of  
carboxylic acid 
 
Inference: 
 The FTIR study revealed that there is no interaction between the drug and polymer in the 
optimized formulation Q1. Hence it can be concluded that the major peaks of the drug are not 
affected by the excipients.
 24,34
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9.3.2 PHARMACEUTICAL EVALUATIONS
 
9.3.2.1 Percentage Yield
38
: 
 Percentage yield of various formulations are depicted in the table 20 and figure 28. 
Table 20: Percentage yield 
Formulation code 
Theoretical yield 
(g) 
Practical yield 
(g) 
Percentage yield 
(% w/w) 
F1 1.860 1.48 79.570 
F2 1.240 0.973 78.468 
F3 1.860 1.56 83.870 
P1 1.860 1.688 90.753 
P2 1.860 1.645 88.441 
P3 1.860 1.570 84.409 
Q1 1.860 1.723 92.634 
Q2 1.860 1.680 90.323 
Q3 1.860 1.500 80.645 
 
 
Figure 28: Percentage yield of Microspheres 
 
Inference: 
The percentage yield was found in the range of 79.57 to 92.634% w/w. The results 
indicated that the formulation containing chitosan-pectin combination (1: 1 ratio) yields 
better percentage of Mesalamine magnetic microspheres. 
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9.3.2.2 Drug Content and Entrapment Efficiency
24,28,33 
 The content of active ingredients of various formulations was analyzed using UV 
spectrophotometer at 230 nm. The results of percentage drug content are depicted in table 21 
and figure 29. 
Table 21: Drug Content of Formulated Microspheres 
Formulation code Drug Content (%w/w) SD (n = 3) 
F1 85.058 1.68 
F2 84.393 3.262 
F3 72.157 5.42 
P1 85.698 3.614 
P2 78.127 0.24 
P3 70.601 1.37 
Q1 86.369 0.41 
Q2 76.833 0.97 
Q3 69.964 2.7 
 
               
Figure 29: Drug content of Formulated Microspheres 
 
Inference: 
The percentage of drug content ranged from 69.964 to 86.369% w/w. The 
formulation Q1 found to have higher drug content. 
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9.3.2.3 Drug Loading Capacity
100 
 The Drug loading capacity of various formulations was analyzed using UV 
spectrophotometer at 230 nm. The results of percentage drug content are depicted in table 22 
and figure 30. 
       Table 22: Drug Loading Capacity of Formulated Microspheres 
Formulation code Drug Loading (%) SD (n = 3) 
F1 17.289 0.34 
F2 22.828 0.672 
F3 29.093 2.20 
P1 19.131 0.302 
P2 21.667 0.066 
P3 19.131 0.37 
Q1 17.540 0.059 
Q2 20.819 0.26 
Q3 28.209 1.09 
 
 
       Figure: 30 Drug Loading of Formulated Microspheres 
Inference 
  The drug loading capacity ranged from 17.289 – 28.209 %w/w and from the result it is 
clear that the drug loading capacity increases with increase in drug:polymer ratio.
25,101. 
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9.3.2.4 Swelling Studies
33,38,63 
 The swelling ability of various microsphere formulations in PBS pH 7.4 was 
determined and the results of their  % swelling  (% SR) was shown in table 23 and figure 31. 
               Table 23: % Swelling  Vs. % Drug content 
Formulation code 
Swelling Ratio 
(SR) 
Drug Content 
 (%w/w) 
F1 32.4 85.058  
F2 36.0 84.393  
F3 38.0 72.157  
P1 20.1 85.698 
P2 21.0 78.127 
P3 21.5 70.601 
Q1 20.0 86.369  
Q2 26.0 76.833 
Q3 33.0 69.964 
 
 
       Figure 31: Percentage Swelling Vs. Percentage Drug content 
Inference  
 The swelling ratio of microspheres was found in the range of 0.200 to 0.380. The data 
revealed that the SR of microspheres increases with decrease in drug content since water 
molecules cannot acquire much space in MM with higher drug entrapment.
33 
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9.3.2.5  EVALUATION OF FLOW PROPERTIES18,38,39,100
 
 Table 24:  Flow Properties of Mesalamine Magnetic Microspheres 
Formulation 
code 
Bulk 
density(g/ml) 
Tapped 
density(g/ml) 
Compressibility 
index (%) 
Hausner’s 
ratio 
Angle of 
repose (°) 
F1 0.335± 0.013 0.427 ± 0.035 21.11 ± 4.189 1.270± 0.065 26.31± 2.257 
F2 0.316 ± 0.008 0.366 ± 0.013 13.52± 1.753 1.156± 0.023 
29.3± 1.892 
 
F3 0.297 ±0.00 0.337 ± 0.007 12.04± 1.676 1.137± 0.024 27.281± 0.571 
P1 0.467 ± 0.009 0.523± 0.017 10.203± 1.566 1.112± 0.023 29.55± 1.536 
P2 0.385 ± 0.011 0.427± 0.009 7.550± 3.954 1.108± 0.028 27.36± 0.953 
P3 0.33 ± 0.0 0.363± 0.005 6.38± 3.008 1.069± 0.036 28.16± 1.076 
Q1 0.415 ± 0.0 0.448± 0.016 6.775± 1.994 1.07± 0.022 26.57± 0.844 
Q2 0.416 ± 0.008 0.484± 0.017 13.808± 1.900 1.161± 0.025 30.28± 1.78 
Q3 0.203 ± 0.011 0.517± 0.022 12.29± 4.174 1.142± 0.057 27.24± 1.045 
*Mean+SD(n=3) 
9.3.2.5.1 Bulk Density 
The results of bulk density measurements are shown in table 24 and figure 32.  
 
    Figure 32: Bulk density of Microspheres 
 The bulk density was found in the range of 0.203 to 0.467 g/ml for various formulations. 
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9.3.2.5.2 Tapped density 
The results of tapped density measurements are shown in table 24 and figure 33. 
 
     Figure 33: Tapped density  
The tapped density was found in the range of 0.337 to 0.523 g/ml for various formulations. 
 
9.3.2.5.3 Angle of repose 
The results of angle of repose measurements are shown in table 24  and figure 34. 
 
    Figure 34: Angle of repose 
The angle of repose of various formulations ranges from 26.31
o
 to 30.28
o
 indicating 
excellent flow of microspheres  
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9.3.2.5.4 Compressibility Index (%) 
 The results of compressibility index measurements are shown in table 24  and figure 35.  
 
     Figure 35: Compressibility index (%) 
The compressibility index was found in the range of 6.38 to 21.11% for various formulations 
and shows excellent-passable flow properties.  
9.3.2.5.5 Hausner’s Ratio  
The results of Hausner’s Ratio measurements are shown  in table 24  and figure 36. 
 
Figure 36:  Hausner’s Ratio 
The Hausner’s ratio of the formulations were found in the range of 1.07 to 1.161and shows 
excellent-good flow properties. 
Inference  
The flow properties of the microspheres were evaluated. It is found that the flow of 
microspheres are optimum and within the range.
18
 It indicates good flow characteristics. 
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9.3.2.6   in- vitro RELEASE STUDIES
24,115
 
The in- vitro release study of Mesalamine magnetic microspheres was done using basket 
apparatus using a mixture of 45ml of 0.1N HCl  and 855ml of  PBS pH 7.4 as the dissolution 
medium . The results are shown in table 25-27 and figure 37-39. 
9.3.2.6.1 Table: 25 Percentage drug release of Pure Drug, Formulation F1 to F3 
Time 
(hours) 
Pure Drug F1 F2 F3 
0 0 0 0 0 
0.5 29.160 - - - 
1 93.400 4.464 3.960 7.200 
1.5 110.48 - - - 
2 - 9.024 10.092 10.480 
3 - 15.916 11.240 19.348 
4 - 21.404 18.860 25.212 
5 - 48.520 24.364 45.504 
6 - 63.908 47.180 68.788 
7 - 89.820 81.998 99.400 
8 - 
  
106.060 
*Mean+SD(n=3) 
                 
Figure 37: Percentage Drug release of Mesalamine Magnetic Microspheres (Chitosan)  
It is observed that all the formulations gave the drug release less than 10±1% in first 2 hrs 
in PBS (pH 7.4) As drug: polymer ratio increases (i) drug release decreases due to the formation 
of a rigid polymer matrix and (ii) particle size increases, thus surface area is decreased and the 
drug release is retarded for the formulation F3 with the highest drug:polymer ratio (1:3).
13 
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9.3.2.6.2 Table 26: Cumulative percentage drug release of Formulation P1 to P3 
Time 
(hours) 
Pure Drug P1 P2 P3 
0 0 0 0 0 
0.5 29.160 - - - 
1 93.400 46.800 43.200 28.8 
1.5 110.48 - - - 
2 - 55.700 53.520 40.20 
3 - 64.288 58.856 46.68 
4 - 107.482 98.060 80.056 
5 - 
 
- 100.296 
*Mean+SD(n=3) 
 
Figure 38: Percentage Drug release of Mesalamine Magnetic Microspheres (Pectin) 
 
The results indicated that formulation with lesser drug–polymer ratio shows faster 
drug release. All formulations from P1 to P3 showed a burst release of 50+5% in 2h itself. 
The burst release may be due to high solubility of pectin.
115
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9.3.2.6.3 Table 27: Cumulative percentage drug release of Formulation Q1 to Q3 
Time 
(hours) 
Pure Drug Q1 Q2 Q3 
0 0 0 0 0 
0.5 29.160 - - - 
1 93.400 6.840+ 0.294 15.840 10.44 
1.5 110.48 - - - 
2 - 14.078+ 0.295 18.808 14.46 
3 - 21.476+ 0.452 21.600 19.218 
4 - 30.808+ 0.625 43.872 35.884 
5 - 58.243+ 0.349 64.994 79.282 
6 - 76.534 +0.449 89.832 90.520 
7 - 95.137 +0.162 104.006 103.618 
8 - 99.019+ 0.181 - - 
9 - 100.64 +0.332 - - 
*Mean+SD(n=3) 
 
       Figure 39: % Drug release of Mesalamine Microspheres (Chitosan-Pectin combination) 
 
It is observed that the formulations Q1, Q2 and Q3 containing polymer mixture 
(chitosan and pectin in the ratios 1:1, 1:2, and 1:3 respectively) was able to protect the 
formulation from premature drug release when compared to those formulations containing 
pectin alone (namely, P1, P2 and P3).The results also indicates that the chitosan-pectin 
microspheres substantially retarded the drug release and showed the best result for the one 
with higher chitosan content (i.e., Q1 formulation). The inter polymer complex that could be 
formed between carboxyl groups of pectin and the amino groups of chitosan, may be 
responsible for such delayed drug release.
68
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9.3.2.6.4   EFFECT OF POLYMER TYPE ON in- vitro DRUG RELEASE
68 
The effect of polymer type on in- vitro drug  release  was compared. The results are 
shown in table 28 and figure 40.
 
    Table 28: Percentage drug release of Formulations F1, P1 and Q1  
Time 
(hours) 
F1 P1 Q1 
0 0 0 0 
1 4.464 46.800 6.840 
2 9.024 55.700 14.078 
3 15.916 64.288 21.476 
4 21.404 107.482 30.808 
5 48.520 - 58.243 
6 63.908 - 76.534 
7 89.820 - 95.137 
8 - - 99.019 
9 - - 100.640 
*Mean+SD(n=3) 
 
        Figure 40: Percentage drug release of Formulations F1, P1 and Q1 
It is observed that the formulation Q1 containing polymer mixture (chitosan and 
pectin in the ratio (1:1) was able to protect the formulation from premature drug release when 
compared to those formulation containing pectin alone (P1).The results also indicates that the 
chitosan-pectin microspheres substantially retarded the drug release upto 9 hours. The inter 
polymer complex that could be formed between carboxyl groups of pectin and the amino 
groups of chitosan, may be responsible for such delayed drug release.
68
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9.3.2.9   RELEASE KINETICS AND MECHANISM
37
 
The kinetics of drug release for optimized  Mesalamine  loaded Chitosan-Pectin (1:1ratio)  
magnetic microspheres Q1 was shown in the table 29 and figure 41 -45.  
Table 29: Mechanism of release kinetics 
Time 
in 
Hours 
% 
Cum. 
Drug 
release 
% Cum. 
Drug 
remaining 
Log% 
Cum. 
drug 
remaining 
Square 
root of 
time 
Log 
time 
Log% 
cum. 
Drug 
release 
Cube root 
of % drug 
remaining 
0 0 100 2 0 -α -α 4.642 
1 6.84 93.16 1.969 1 0 0.835 4.533 
2 14.078 85.922 1.934 1.41421 0.30103 1.148 4.413 
3 21.476 75.524 1.878 1.73205 0.47712 1.332 4.227 
4 30.808 69.192 1.84 2 0.60206 1.489 4.105 
5 58.243 41.757 1.621 2.23607 0.69897 1.765 3.469 
6 76.13 23.87 1.378 2.44949 0.77815 1.881 2.879 
7 95.137 4.863 0.867 2.64575 0.8451 1.978 1.694 
8 99.019 0.981 0.008 2.82843 0.90309 1.996 0.994 
 
 
 
Figure 41: Zero Order Kinetics for Optimized Formulation Q1 
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Figure 42: First Order Kinetics for Optimized Formulation Q1 
        
Figure 43: Korsmeyer Peppas Release Kinetics for Optimized Formulation Q1 
         
Figure 44: Hixon Crowell Kinetics for Optimized Formulation Q1 
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Figure 45: Higuchi Diffusion Kinetics for Optimized Formulation Q1 
 
 
The coefficient of determination (R
2
) was taken as criteria for choosing the most    
appropriate model. The R
2
 values of various kinetic models are in table 30. 
Table 29: R
2 
values of various kinetic models 
 
Kinetic model 
 
Coefficient of determination (R
2
) 
Zero order 
 
0.956 
First order 
 
0.745 
Korsmeyerand Peppas 
 
0.975 
Hixson-Crowell 
 
0.864 
Higuchi 
 
0.797 
 
 The order of drug release was found to be Zero order, in which regression value was 
0.956. 
 The ‘n’ value of Korsmeyer peppas equation was found to be 1.372. From this it was 
concluded that the drug release follows a Super-Case II transport  in which the  drug 
release mechanism may be due to polymer relaxation (erosion) alone.
37,45,44
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9.3.2.10   STABILITY STUDIES 
28,45,108 
 
 During storage at different temperature and humidity conditions (room temperature as 
well as  in stability chamber at 40±2°C/75±5% RH), the optimized formulation Q1 was assayed 
at regular intervals of 15
th
, 30
th
 and 60
th
 days. The results are shown in table 30 and figure 46. 
 
Table 30: Stability Studies 
Parameter 
Initial 15th day 30th day 60th day 
Ambient 
temperature 
& humidity 
40±2°C / 
75±5% 
RH 
Ambient 
temperature 
& humidity 
40±2°C / 
75±5% 
RH 
Ambient 
temperature 
& humidity 
40±2°C / 
75±5% 
RH 
Ambient 
temperature 
& humidity 
40±2°C / 
75±5% 
RH 
 
Physical 
appearance 
No  
change 
No  
change 
No  
change 
No 
change 
No  
change 
No  
change 
No  
change 
No  
change 
 
Drug 
Content 
 
86.365 
+0.41 
86.365 
+0.41 
85.945 
+ 0.12 
86.102 
+0.023 
85.892 
+0.196 
85.997 
+0.074 
85.17  
+0.18 
84.867 
+ 0.07 
                    *Mean+SD(n=3) 
 
 
Figure 46: Stability Data of Optimized  formulation 
 
Inference  
As per the stability data obtained, there is no significant change either in physical 
appearance or in drug content. Thus the formulation was stable at different conditions of 
temperature and humidity.
28,44
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Preclinical in-vitro Screening Studies  
9.3.2.7 in-vitro DRUG RELEASE STUDY IN MICROFLORA ACTIVATED SYSTEM
98,102,96,89
 
The effect  of ß-glucosidase and pectinase enzymes on the drug release of optimized 
formulation Q1  is shown in the table 31 and figure 47. 
Table 31: Cumulative percentage drug release of  Q1 with & without Enzyme
 
Time 
(hours) 
Cumulative % Release 
Without Enzyme 
With ß-glucosidase & 
pectinase enzymes 
0 0 0 
1 6.840+ 0.294 9.720 
2 14.078+ 0.295 17.694 
3 21.476+ 0.452 36.152 
4 30.808+ 0.625 57.772 
5 58.243+ 0.349 83.004 
6 76.534 +0.449 97.45 
7 95.137 +0.162 106.144 
8 99.019+ 0.181 - 
9 100.64 +0.332 - 
*Mean+SD(n=3) 
 
            Figure 47: % Drug release of Optimized Formulation with & without enzymes 
 
In the presence of enzymes (ß-glucosidase containing a chitosinase enzyme which can 
hydrolyze chitosan polymer and pectinase enzyme which can hydrolyze pectin polymer), the 
polysaccharides undergoes a faster erosion process resulting in the rapid dissolution in the  
medium ; eventually facilitating faster drug release with a maximum of 106.144% achieved 
within 7 hours.
37,70 
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9.3.2.8  in- vitro ANTI-INFLAMMATORY ACTIVITY OF OPTIMIZED FORMULATION85,93 
The in- vitro percentage inhibition of albumin denaturation method was used to evaluate anti-
inflammatory potential of the formulation Q1 and the results are shown in the table32 and fig 48.
 
 
Table 32: Inhibition of protein denaturation assay of optimized formulation
 
Q1 
 
Time 
(hours) 
% Inhibition 
Pure Drug Formulation Q1 
0 0 0 
0.5 39.858 - 
1 80.527 18.450 
1.5 82.657 - 
2 - 24.544 
3 - 28.701 
4 - 41.886 
5 - 63.692 
6 - 73.120 
7 - 80.730 
8 - 81.237 
9 - 82.252 
 
 
 Figure 48:  %Inhibition of Protein Denaturation of Optimized formulation Q1 
 
Inference 
 
The results shows that optimized formulation Q1 showed 82% of albumin denaturation 
within 9 h which clearly indicates that Q1 also exhibited a satisfactory dose-dependent anti-
inflammatory activity as that of the pure drug.
93
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9.3.3 MAGNETIC CHARACTERIZATION
1 
 
9.3.3.1 Percentage Magnetite Content
28,24,78,38
  
  Magnetite (Fe3O4) content in the prepared magnetically responsive microspheres 
was determined by the conventional titrimetric method using thiosulphate and potassium iodide 
for quantitative analysis and the results are shown in table 33 and figure 49. 
 
Table 33:  Percentage Magnetite Entrapped 
Formulation code 
Magnetite entrapped 
(%) 
F1 21.450 
F2 26.813 
F3 29.494 
P1 21.885 
P2 22.522 
P3 24.857 
Q1 22.522 
Q2 25.929 
Q3 28.610 
 
            
Figure 49: Magnetite content of Formulated Microspheres 
The amount of magnetite content per microspheres of weight equivalent to 50mg of 
magnetite was determined in all formulations. The maximum magnetite content was found to 
be 29.494%  in formulation F3.It was observed that entrapment of magnetite increased with 
increase in concentration of polymer added in consecutive formulations and the values range 
from 21.450- 29.494%. The optimum magnetite content is generally between 22-50%
.24,28,82
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9.3.3.2 Magnetic Separation Study
42 
 
The formulated magnetic microspheres were dispersed in water to study their 
magnetic separation behavior. Figure shows that the magnetic microspheres rapidly move 
towards the direction of magnetic field in an aqueous solution under the externally applied 
magnetic field in 30s. After the ceassation of external magnetic field, the microspheres 
evenly spread out in water again with bottle shaking. 
 
Figure 50: magnetic separation 
 
 
9.3.3.3 Magnetism Assessment using Vibrating Sample Magnetometer (VSM)
29,42,78 
 
The magnetization curves of the magnetically responsive microspheres were taken at 
room temperature using Vibrating Sample Magnetometer (VSM) to study the superpara 
magnetic behavior by finding the saturation magnetization value.  
 
The prepared mesalamine magnetic microspheres displayed super-paramagnetic 
property, and the saturation magnetization value was found to be 9.1146emu/g, which is 
sufficient for magnetic separation from water solution. The saturation magnetization of the 
microspheres was much lower than that of bulk magnetite (84emu/g) which may be attributed 
to the incorporation of thick polymer layer on the magnetite particles. As a result, a narrow 
hysteresis loop was obtained which is shown in the result obtained from VSM. The results are 
given in table 34 and figure 51. 
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Figure: 51 Magnetization curves obtained by VSM for optimized formulation 
 
Table 34:  Parameters analysed by VSM 
S. No Parameter Result 
1 Acquisition Mode Point by Point 
2 Coercivity (Hci) 285.52 G 
3 Magnetization (Ms) 9.1146E-3 emu 
4 Mass 35.830E-3 g 
5 Maximum Field 15000 G 
6 Mr, Negative -1.7282E-3 emu 
7 Mr, Positive 2.6995E-3 emu 
8 Ms, Negative -9.0973E-3 emu 
9 Ms, Positive 9.1320E-3 emu 
10 Number of Points 101 
11 Retentivity (Mr) 2.2138E-3 emu 
12 Sensitivity -4.1000 emu 
 
SUMMARY AND CONCLUSIONS 
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 The aim of the present study was to formulate Magnetically Responsive Mesalamine 
Microspheres by solvent evaporation method by using biodegradable polymers Chitosan 
and Pectin and to carry out the various pharmaceutical and magnetic characterizations, to 
study the effect of polymer type on in-vitro drug release and preclinical in-vitro screening 
studies such as in-vitro release studies using  microflora activated system and in-vitro 
anti-inflammatory activity. 
 
 Chemical compatibility study was performed using FTIR spectroscopy. FTIR 
spectroscopy studies indicated that the Mesalamine is compatible with polymers. The 
spectra showed no changes in the major peaks thus confirming no interactions between 
drug and polymers.  
 Calibration curvs of Mesalamine was constructed in Phosphate Buffer Saline pH7.4. 
 Magnetite (Fe3O4) (used as magnetic carrier) was chemically synthesised using 
precipitation method.  
 In the present study, 9 formulations were prepared in total by using Chitosan and Pectin 
as polymer in different ratios (1:1, 1:2 and 1:3) of each polymer and combination of two 
polymers. Also, the effect of polymer type was studied. 
 The morphology of optimized formulation was studied by SEM analysis and found that 
shape of microspheres were discrete, spherical and was satisfactory. 
 The mean particle size was found using microscopic analysis, which varied as the drug 
and polymer ratio changes. 
 The drug content for all formulations was found to be in the range of 69.964 to 
86.369%w/w. The formulation Q1 had the highest drug content. 
 The drug loading was found to be in the range 17.289 – 28.209 %w/w and the data 
revealed that the drug loading capacity increases with increase in drug:polymer ratio. 
 The swelling ability of various microsphere formulations in PBS pH 7.4 was determined 
and their swelling ratio was found in the range of 0.200 to 0.380. The data revealed that 
the SR of microspheres increases with decrease in drug content since water molecules 
cannot acquire much space in MM with higher drug entrapment. 
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 The in- vitro drug release study was carried in phosphate buffer saline pH 7.4 as per the 
prescribed procedure. 
 Among the different formulations, Q1 gave satisfactory results by releasing 100.64 % in 9 
hours. The results indicate that the chitosan-pectin microspheres substantially retarded the 
drug release and showed the best result for the one with higher chitosan content (i.e., Q1 
formulation). The inter polymer complex that could be formed between carboxyl groups 
of pectin and the amino groups of chitosan, may be responsible for such delayed drug 
release. 
 The effect of polymer type on in-vitro drug release was compared and from the results, 
the formulation Q1 has been selected as the optimized formulation substantially retarded 
the drug release upto 9 hours. 
  The in-vitro release study of optimized formulation Q1 was applied to various kinetic 
models to predict the mechanism of drug release. The drug release was found to follow 
zero order kinetics. In Korsemeyer Peppas equation, the n value was 1.372, indicating 
anomalous diffusion or non-fickian diffusion, probably Super-Case II transport in which 
the drug release mechanism may be due to polymer relaxation(erosion) alone.  
 Stability studies had been carried out for optimized formulation at a temperature of 
40±2°C / 75±5% RH and at ambient room temperature and humidity for a period of 60 
days. The results revealed that there is no significant change either in physical appearance 
or in drug content. Thus the formulation was stable at different conditions of temperature 
and humidity. 
 in-vitro drug release study of optimized formulation was carried out in Microflora 
Activated System containing ß-glucosidase and pectinase enzymes (in an attempt to 
substitute for rat cecal and colonic enzymes and thereby limiting animal use in the initial 
screening study). The results show that the polysaccharides undergoes a faster erosion 
process eventually facilitating faster drug release. 
 in-vitro percentage inhibition of albumin denaturation method was used to evaluate anti-
inflammatory potential for the optimized formulation and the results shows that Q1 
formulation has exhibited a satisfactory dose-dependent anti-inflammatory activity for 
over a period of 9 hrs. 
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 Magnetite (Fe3O4) content in the prepared magnetically responsive microspheres was 
determined by the conventional titrimetric method using thiosulphate and potassium 
iodide. The maximum magnetite content was found to be 29.494%  in formulation F3.It 
was observed that entrapment of magnetite increased with increase in concentration of 
polymer added in consecutive formulations and the values range from 21.450- 29.494%. 
The optimum magnetite content is generally between 22-50%. 
 The magnetization curves of optimized formulation Q1 was taken using Vibrating Sample 
Magnetometer (VSM) to study the super-paramagnetic behaviour. The result shows that 
the saturation magnetization value was found to be 9.1146emu/g, which is sufficient for 
magnetic separation from water solution. A narrow hysteresis loop was obtained from 
VSM which confirms that the formulation displayed a satisfactory super-paramagnetic 
property.  
 It can be concluded that the Magnetically Responsive Mesalamine Microspheres offer a 
localized drug delivery only at the target site by the combined effect of physical 
approach (utilizing the principle of magnetic targeting with an intention to produce a 
depot near the target organ) and biochemical approach (using biodegradable polymers 
chitosan and pectin for drug release in a controlled manner). By producing a depot near 
the target organ, unwanted distribution of drug to non target organ can be avoided.  
 The results of the study revealed Magnetically Responsive Mesalamine Microspheres is 
an effective strategy for localized drug delivery only at the target site for the treatment of 
Irritable Bowel Diseases and thereby minimizing the dose and drug induced toxicity. 
 
FUTURE SCOPE 
  
 in-vitro screening using cell culture models 
 in- vivo screening using animal models (using gamma scintillography).  
 Pharmacokinetic and toxicity study 
 
           The adoption of magnetic particles for targeted delivery is minimal and most of the 
work is in the basic research phase. Hence their potential is yet to be realized fully. The 
future holds great promise for its systematic investigation and exploitation. 
BIBLIOGRAPHY 
Department of Pharmaceutics, Madras Medical College Page 125 
 
1. Prabhu Chakrapani et al. Encapsulation of Methotrexate loaded magnetic microcapsules 
for magnetic drug targeting and controlled drug release. Journal of magnetism and 
magnetic materials 380: 2015.285-294. 
2. Manivannan rangasamy and Kugalur Ganesan Parthiban. Recent Advances in Novel Drug 
Delivery Systems. IJRAP. 2010; 1(2); 316- 26.  
3. Available at: www. Wikipedia.org/wiki/Targeted_drug_delivery. Accessed dt:13.6.2015.   
4. Amit Chandna, Deepa Batra, Satinder Kakar, Ramandeep Singh. A review on target drug 
delivery : Magnetic microspheres. Journal of Acute Disease; 2013;189-195. 
5.  Ratnaparhi Mukesh.P. et al. Colon targeted drug delivery system. International journal of 
Pharma research and review 2013: 2(8): 33-42  
6. Sharma Anuj et al. Colon targeted drug delivery using different approaches .IJPSR Sep 
2010:1(1):60-66. 
7. Sateesh Kumar Vemula, Prabjakar Reddy Veerareddy. Different Approaches to Design 
and Evaluation of Colon specific Drug Delivery Systems. IJPT. 2009:1; 1-35. 
8. Danda Sreelatha et al. Colon targeted drug delivery: a review on primary and novel 
approaches. JGTPS.sep 2013:4(3); 1174-1183. 
9.  Mukherjee.S, Bandyopadhyay. P. Magnetic microspheres: A latest approach in novel 
drug delivery system. JPSI .Sep-Oct 2012.1(5):21-25. 
10. Elisangela P da Silva et al. Covalent TiO2/Pectin microspheres with Fe3O4 nanoparticles 
for magnetic field –modulated drug delivery. IJBM 67 (2014):43-52. 
11. Satinder Kakar, Deepa Batra1, Ramandeep Singh. Preparation and evaluation of magnetic 
microspheres of mesalamine (5-aminosalicylic acid) for colon drug delivery. JAD 2013; 
226-231. 
12. Priyanka Lokwani. Magnetic particles for drug delivery: an overview. IJRPBS. Apr-jun 
2011; 2(2):465-473. 
BIBLIOGRAPHY 
Department of Pharmaceutics, Madras Medical College Page 126 
 
13. Deepa Batra et al. Magnetic microspheres as a targeted drug delivery system: an 
overview (review article).JDDR. 2012.1(3):1-16. 
14. Patel Palak, Patel Ghanshyam, Daslaniya Dhiren, Bhimani Bhavin, Shah Ragin. Magnetic 
microsphere-a review. IJHPS.2013:2(1): 4-14. 
15. Nidhi et al. Microparticles as controlled drug delivery carrier for the treatment of 
ulcerative colitis: a brief review. Saudi pharmaceutical journal.2014:1-14. 
16. Ahmed Abd El-Bary,1 Ahmed A. Aboelwafa,1,2 and Ibrahim M. Al Sharabi1. Influence 
of some formulation variables on the optimization of PH-dependent, colon-targeted, 
sustained release Mesalamine Microspheres. AAPS PharmSciTech; March 2012; 13. 
17. Dinesh Kaushik et al. in-vitro Characterization and Cytotoxicity Analysis of 5-
Fluorouracil loaded Chitosan Microspheres for Targeting Colon Cancer. IJPER. 
2010:44(3):274-282. 
18. Kishori L. Deore*, Nilima A. Thombre, Paraag S. Gide. Formulation and development of 
Tinidazole microspheres for colon-targeted drug delivery systems.JPR.6; 2013; 158-165. 
19. Sangeetha Mohanty et al. Multiparticulate Drug Delivery Systems for Colon Targeting. 
IJPPS. 2015: 7(2): 433-436. ISSN: 0975-1491. 
20. Ranjit Singh. Formulation and evaluation of colon targeted drug delivery system. IJPLS. 
Dec 2012; 3(12):2265-2268.   
21. Nitesh Shah et al. Design, development and optimization of colon targeted drug delivery 
system for Crohn’s disease. J.pharm Edu Res .June 2011:2(1).42-49.   
22. Rathod Sudha .S. in-vitro release and in-vivo tissue localization of 5-Fluorouracil loaded 
microspheres. IJPPS. 2014.6(1):78-63. 
23. Goodman and Gilman’s The Pharmacological basis of Therapeutics. 11th edition (2006). 
Chapter 38. 
24. Satinder Kakar and Ramandeep Singh. Preparation of magnetic microspheres of mesalamine by 
phase separation emulsion polymerisation technique. AJPP.2014:8(9).246-258. 
BIBLIOGRAPHY 
Department of Pharmaceutics, Madras Medical College Page 127 
 
25. Naveen K Thakral, Alok R Ray. Daniel Bar-Shalom, André Huss Eriksson. Formulation. 
Quest for target delivery in colon cancer: mucoadhesive Valdecoxib microspheres. 
International journal of nanomedicine.19 may 2011:1057-1068. 
26. Seyda Bucak et al. Magnetic nanoparticles: Synthesis, surface modifications and 
application in drug delivery. INTECH: 165-200. www.dx.doi.org/10.5772/52115. 
27. Anamariya Durduranu-Angheluta et al. Tailored and functionalized magnetic particles 
for biomedical and industrial applications. www.intechopen.com.149-178. 
28. Vyas M.B et al. Design and characterization of Cisplatin magnetic microspheres. 
IJB.2013;4(2):66-72. 
29. Liang Guo et al. Preparation and characterization of Chitosan poly (acrylic acid) 
magnetic microspheres. Marine drugs .2010,8: 2212-2222. 
30. Jeffrey Leach H. Magnetic targeted drug delivery. Thesis for M. Sc in Electrical 
Engineering. Virginia Polytechnic Institute and State University. February 2003. 
31.  Schutt. W. Applications of magnetic targeting in diagnosis and therapy-possibilities and 
limitations –a mini review.HYBRIDOMA.1997;16 (1). 
32. Indian Pharmacopoeia, Ministry of Health and Family Welfare Department, Ghaziabad, 
India: The India Pharmacopoeia Commission 2014;2; 2179-2184.  
33.  Satinder Kakar, Deepa Batra, Ramandeep Singh. Preparation and evaluation of magnetic 
microspheres of mesalamine (5-aminosalicylic acid) for colon drug delivery. JAD 2013: 
226-231. 
34. Sharma Madhu et al. Formulation and Evaluation of Colon Targeted Tablets of 
Mesalazine. Journal of Drug Delivery and Therapeutics. 2012.2(5):24-36. 
35. Ramandeep Singh et al. Magnetic microspheres as a boon over microspheres: a review. 
IJRAPR. April 2015;5(2):68-74. 
36. Vimal Kumar Varma .M. et al. Preparation and in-vitro evaluation of Diclofenac sodium 
loaded ethyl cellulose composite magnetic microspheres .International journal of 
pharmaceutical analysis 2009:1(2);40-45. ISSN:097523079 
BIBLIOGRAPHY 
Department of Pharmaceutics, Madras Medical College Page 128 
 
37. Bala Venkata Pradeep.V, Dr.Grace Rathnam. Development of enteric coated pectin 
matrix tablets of Metronidazole for colon targeting. IJPRD 2011,volume 3(6), August 
2011; 10-16. 
38. Sathinder Kakar & Ramandeep Singh. 6-Thioguanine loaded magnetic microspheres as a 
new drug delivery system to cancer patients .AJPP Aug 2014;8(31):786-793. 
39. Seema Badhana et al. Colon specific drug delivery of Mesalamine using Eudragit S100-
coated Chitosan microspheres for the treatment ulcerative colitis. International current 
pharmaceutical journal.2013;2(3/01):42-48. 
40. Qi Ren et al. Design and fabrication of superparamagnetic hybrid microspheres for 
protein immobilization. School of Chemical and Material Engineering, Jiangnan 
University, Wuxi 214122, People’s Republic of China 
41. Yu Tang et al. Preparation of cellulose magnetic microspheres with “the smallest critical 
size“ and their application for immunocapture. Langmuir article .2010. 
42. Ling-Han-Xiao et al. Fabrication of magnetic –antimicrobial-fluorescent multifunctional 
hybrid microspheres and their properties.Int.J.Mol.Sci.2013.(I4); 7391-7404. 
43.  Available at: www.umm.edu/ulcerative colitis. Acced date: 20.6.2015. 
44. Dinesh Chandra et al. Design and development of Satranidazole microspheres for colon 
targeted drug delivery. IJPCS. Jul-Sep 2012.1(3) ;1161-1167. 
45.  BehinSundara Raj, Shanthi, Rajesh Sreedharan Nair, Punitha Isaac Samraj, Vidya. 
Formulation and Evaluation of Coated Microspheres for Colon Targeting. JAPS. 2013; 
3; S68 – S74. 
46. Available at: www.slideshare.net/AiswariyaChidambaram/targeted-drug-delivery-
technologies-and-applications. Accessed date: 25.6.2015 
47. Shailendra Wasnik, Poonam Parmar. The design of colon-specific drug delivery system 
and different approaches to treat colon disease. Jan-feb 2011.6(2);article-031. 
48. Raymond Rowe C, Paul Sheskey J and Marian Quinn E. Handbook of Pharmaceutical 
Excipients. 6
th
 edition. 
BIBLIOGRAPHY 
Department of Pharmaceutics, Madras Medical College Page 129 
 
49. Lawrence Douziech-Eyrolles et al. Nanovectors for anti-cancer agents based on 
superparamagnetic iron oxide nnaoparticles. International journal of nanomedicine. 
2007:2(4):541-550. 
50. Charles Craig .R, Robert Stitzel .E. Modern Pharmacology with Clinical Applications. 
5
th
 edition:433-434. 
51. Gurunath.S Padgaonkar et al. Formulation and evaluation of oral novel colon targeted 
drug delivery system using natural polymers. IJPI March 2012: 2(3):42-61. 
52. Keerthi. P et al. Magnetic microspheres: a nobel approach. WJPPS 2013.3(1):320-323.  
53. Moharana A.K.et al. Development and Validation of UV Spectrophotometric method for 
the determination of Mesalamine in bulk and tablet formulation. IJPPS. 3(2):19-21. 
54. Surender Verma et al. Current prospective of magnetically triggered microsphere 
towards colonic disease: A review .WJPS 2015: ISSN (print): 2321-3310: ISSN (online): 
2321-3086. 
55. Seyda Bucak et al. Magnetic nanoparticles: synthesis, surface modifications and 
application in drug delivery. INTECH. chapter 7:165-200. 
56. Shailendra Wasnik et al. The design of colon-specific drug delivery system and different 
approaches to treat colon disease .International journal of Pharmaceutical sciences 
review and research.2011: Article 031.6(2):167-175. 
57. Kathiravan Periyasamy & V.P.Pandey. Novel approaches for colon specific drug 
delivery system- a review. Int.J.Pharm pharm sci; 2013; 5(3); 118-122.  
58. Josephine Leno Jenita.J.et al. Formulation and evaluation of microparticles containing 
curcumin for colorectal cancer. JDDT;2012;2(3):125-128. 
59. Available at: A to Z Drug Facts 
60. Amol Paharia. Eudragit –coated pectin microspheres of 5-fluorouracil for colon 
targeting. AAPS Pharm sci tech.2007; 8(1).article.12. 
61. Ivo Safarik et al. Magnetically responsive activated carbons for bio- and environmental 
applications. IRECHE; May 2012.4(N3):346-352. 
BIBLIOGRAPHY 
Department of Pharmaceutics, Madras Medical College Page 130 
 
62. Gordon Morris .A. Polysaccharide drug delivery systems based on pectin and chitosan. 
Biotechnology and Genetic Engineering Reviews. 2010.27: 257- 284. 
63. Ofokansi K C et al. Formulation and evaluation of glutraldehyde –cross linked Chitosan 
microparticles for the delivery of Ibuprofen. Tropical journal of Pharmaceutical research 
Feb 2013.Vol:12(1):19-25.ISSN:1596-9827(electronic). 
64. Meltum CETIN et al. Preparation and characterization of anti-cancer drug –loaded 
implantable PLGA microparticles. Turk J Chem 2010 (34);509-560.doi : 10.3906/kim-
0910-237. 
65. Najmuddin .M. et al. Formulation and in-vitro evaluation of floating microspheres of 
Ketoprofen prepared by emulsion solvent diffusion method .International journal of 
applied pharmaceutics. 2010;2(1) :13-17. 
66. Rajpurohit H. et al. Polymers for colon targeted delivery. Available at: 
www.ncbi.nih.gov/pmc/articles/PMC3178968:1-9. 
67. Sinha V.R. Microbially trigerred drug delivery to the colon. European Journal of 
Pharmaceutical Sciences.2002.18: 3-18. 
68. Nirav Patel .V, Jayvadan Patel K, Shreeraj Shah H, Jagruti Patel J. Design, development 
and in-vitro evaluation of Mesalamine tablets containing Pectin and Chitosan for colon-
specific drug delivery. IJRPS. 2010.1(2):94-102. 
69. Sheth Zankhana et al. Design and development of 5-Fluorouracil loaded biodegradable 
microspheres .IJRAP 2010:1(1); 160-168. 
70. Chourasia M.K, Jain S. K. Pharmaceutical approaches to Colon targeted drug delivery 
systems. J Pharm Pharmaceut Sci. 2003.6(1);33-66. 
71. Available at : www.ccfa.org/ ulcerative colitis. Accessed date 4.10.2015. 
72. Available at www.en.m.wikipedia.org/wiki/iron(II)_sulphate. Accessed date 10.1.2016. 
Brahmankar DM and Sunil Jaiswal B. Biopharmaceutics and Pharmacokinetics – A 
Treaties. 2009. 2
nd
 edition. Vallabh Prakahan; 429, 435-438,453. 
 
73. Tripathi K.D. Essentials of Medical Pharmacology, Jaypee. 6th edition: 664. 
BIBLIOGRAPHY 
Department of Pharmaceutics, Madras Medical College Page 131 
 
 
74. Erica Lira Silva-Freitas et al. Magnetite content evaluation on magnetic drug delivery 
systems by spectrophotometry. AAPS 2011:12(2):521-524. 
 
75. Ramana .G & Krishna Chaitanya .A. Preparation and in-vitro characterization of ethyl-
cellulose coated pectin alginate microspheres of 5-fluorouracil for colon targeting .JAPS 
2011:1(8):170-176. 
 
76. Nikoletta Fotaki et al. Biorelevant dissolution methods and applications in in-vitro –in-
vivo correlations for oral formulations .The open drug delivery journal 2010:4:2-30. 
 
77. Available at: http://shodhganga.inflibnet.ac.in/characterization of microspheres.86-96. 
 
78. Maria Christina et al. Room temperature co-precipitation synthesis of magnetite 
nanoparticles in a large pH window with different bases. Materials 2013;6,5549-5567. 
 
79. James Ritter.M, Leonel Lewis .D, Timothy Mart G.K, Albert Ferro. A Textbook of 
Clinical Pharmacology and Therapeutics. 5
th
 edition: 255. 
 
80. Heming Huang et al. Mossbauer spectroscopy of protein-passivated iron oxide 
nanoparticles springer science plus business media B.V.2011.Doi:10.1007-s10751-011-
0502-6. 
 
81. Samreen Kaur Randhawa et al. Magnetic microspheres –promising drug delivery system 
for cancer therapy .International journal of natural product science 2012;sp issue.1. 
 
82. Pornsak Sriamornsak et al. Swelling and erosion of pectin matrix tablets and their impact 
on drug release behavior. EJPB 2007;67;211-219.doi: 10.1016/j.ejpb.2006.12.014. 
 
83.  Fransisca Leonard et al. Screening of Budesonide nanoformulations for the treatment of 
IBD in an inflamed 3D-cell culture model. Altex. 2012.29, 3/12:275-285. 
 
84. Kalyani Awala. B et al. Preparation and evaluation of herbal gel containing 
Clerodendrum serratum for anti-inflammatory activity. Pelagia research Library.2014. 
5(4):47-54. 
 
BIBLIOGRAPHY 
Department of Pharmaceutics, Madras Medical College Page 132 
 
85. Morusukeerthana et al. Formulation and evaluation of Secnidazole colon targeting drug 
layered pellets .IJPRLS 2013;1(1);27-33. 
 
86. Purushotham Reddy M; Two simple spectrophotometric methods for the estimation of 
mesalamine in bulk sample and its pharmaceutical dosage forms; Global journey of 
Pharmacology;2011;5(2); 101-105. 
 
87. Erxi Chi et al. Development of phosphonate-terminated magnetic mesoporous silica 
nanoparticles for pH controlled release of Doxorubicin and improved tumour 
accumulation. Asian journal of pharmaceutical sciences 2014; 9:317-323. 
 
88. Biraju Patel D et al. Development and evaluation of pectin based colon targeted herbal 
drug delivery system. AJPP July 2012; 6(25); 1815-1820. 
 
89. Albert Li P. Preclinical Screening Assays for drug-like properties. Drug Discovery 
Today: Technologies. 2005.2(2):179-185. 
 
90. Surender Verma et al. Formulation, evaluation and optimization of osmotically 
controlled colon targeted drug delivery system. JPSR 2011.3(9): 1472-1485. 
 
91. Forbes .A. et al. Review article, oral, modified –release Mesalasine formulation 
proprietary versus generic. Aliment pharmacology and therapeutics 2003; 7;1207-1214. 
 
92. Rashmi Sareen et al. Topical gel incorporated with non-ionic surfactant based solid –
lipid microspheres of ketoprofen: physicochemical analysis and anti-inflammatory 
evaluation. International journal of pharmacy and pharmaceutical sciences.2015; 7(10); 
199-206. 
 
93. Schwerdt et al. Magnetic field – assisted gene delivery achievements and 
therapeuticpotential; 2012; 1(2); 116-126.doi: 10.2174/156652312800099616. 
 
94. Padmanabhan .P et al. Evaluation of in-vitro anti-inflammatory activityof herbal 
preparation, a combination of 4 medicinal plants. International Journal of applied 
medical sciences 2012; 2(1); 109-115. 
 
BIBLIOGRAPHY 
Department of Pharmaceutics, Madras Medical College Page 133 
 
95. Poonam Kushwaha et al. Design and fabrication of Tramadol HCL loaded multi 
particulate colon targeted drug delivery system. Journal of chemical and pharmaceutical 
research 2011.3(5); 584-595. 
 
96. Prathap .M. Colon Targeted Drug Delivery System–a review. TIJRPJK.2014; 3(5); 429-
437. 
 
97. Hua Zhang et al . An in-vitro evaluation of a chitosan containing multiparticulate system 
macromolecules delivery to the colon. International journal of pharmaceutics 2002; 
239;197-205. 
 
98. Juan Carlos Cabrera. Drug Encapsulation in Pectin Hydrogel beads- a systematic study 
in simulated digestive media. IJPPS. 2014. 3(5): 292-299. 
 
99. Josephine Leno Genita .J. et al. Formulation and evaluation of compression coated 
tablets of Mesalazine for colon delivery. International journal of pharm .tech. research; 
2010;2(1);535-541. 
 
100. Mazumder .R. et al. Formulation, development and in-vitro release effects of ethyl  
cellulose coated pectin microspheres for colon targeting .2013;6;(5); 138-144. 
 
101. Available at: www.inflibnet.ac.in/bitstream 07_chapter2, Magnetism; pg 13-24. 
 
102.Rukhsar Iqbal Wasta et al. Evaluation of in-vitro anti-inflammatory activity of   
      Ovoutoline liquid formulation against the denaturation of protein.WJPPS;2015;4(4): 
1190-1194. 
 
103.Vijaya Muthumanikandar .R, Sudeesh Edavalath & Saravanakumar.K. Design and 
       evaluation of Mesalamine tablet for colon specific drug delivery. IJDDR. July 
      -sep 2011;3(3);197-212. 
 
105.Thomas Hartung. Food for thought: Look back in Anger – What Clinical Studies Tell 
Us  About Pre clinical Studies. ALTEX 30, 3/13: 275-291. 
 
BIBLIOGRAPHY 
Department of Pharmaceutics, Madras Medical College Page 134 
 
106. Lalit Jejurkar & K.K.Tapar . Preparation and characterization of Mesalamine solid 
       dispersions by kneading method. IJPSR;2011;2(10):2623-2628. 
 
107. Yadev AV and Yadav VB. Improvement of physicochemical properties of Mesalamine 
with hydrophilic carriers by solid dispersion (kneading) method. RJPT oct-dec 
2008;422-425. 
 
108. SADC guideline for stability testing March 2004:1: 1-44. 
 
109. Available at www.drugbank.ca/drugs. Accessed date: 17.1.2016. 
 
110. Takale A.A et al.  Preparation and characterization of Mesalamine solid dispersion by 
kneading  method. International Journal of  Universal Pharmacy and Pharmaceutical 
Sciences. 2013. ISSN: 2249-6793. 
111. Vyas and Khar. Targeted & Controlled drug delivery Novel carrier System. 1
st
 edition. 
New  Delhi:CBS Publishers and Distributors. 2002; 458-483. 
 
112. Sonali.S.Bharate et al. Interactions and incompatibilities of pharmaceutical excipients     
        with active pharmaceutical ingredients : a comprehensive review.IPEC;2010:1(3):3-26. 
 
113. Sanjay Bajaj et al. Stability testing of pharmaceutical products. 
        JAPS;2012; 02(03):129-138. 
 
114.  Murat Turkoglu & Timucin Ugurlu. In-vitro evaluation of pectin-HPMC compression 
         coated 5-aminosalicylic acid tablets for colonic delivery.EJPB;53(2002);65-73. 
 
115. Available at www.authorstream.com/Presentation/geetparu- 559901- targeted- drug- 
delivery system. 
 
 
 
 
 
